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  Tuberculosis (TB) is a bacterial disease treated with antibiotics. But because of the 
prevalence, nature, and lengthy treatment of the disease, TB is in need of new antibiotics.  But, 
big pharma companies, who have historically been responsible for developing many of the 
world’s critical antibiotic agents, have significantly decreased investment in antibiotic research 
and development (R&D). Many sectors are devoted to addressing this issue including non-profit, 
commercial, government, and academia. Specifically in academia and regards to TB, Regis 
University has pursued research in the identification of inhibitors of Mycobacterium 
tuberculosis class IIa fructose-1,6-bisphosphate aldolase (MtFBA), an essential enzyme 
in Mycobacterium tuberculosis. If successful, these inhibitors could serve as potential scaffolds 
for future therapeutic agents to combat TB. The antibiotic funding problem cannot be tackled 
without significant cooperation and collaboration. The issue should be addressed with increased 
collaboration between small biotech companies and big pharma, increased publicity for bacterial 
diseases, reevaluation of clinical trials, and inspiring the next generation of chemists to simply 
do science. 
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INTRODUCTION 
This thesis aims to address one of the most pressing needs in the fight against 
bacterial diseases: the development of novel antibiotics. Tuberculosis (TB) is one such 
disease in dire need of new antibiotics. Historically, big pharma companies such as Pfizer 
and AstraZeneca, have been responsible for the development of these greatly needed 
drugs. However, these companies have recently decreased funding in this area. This 
thesis is laid out in four chapters to illustrate the need for novel TB antibiotics, the antibiotic 
research and development (R&D) problem, ways in which the problem is helped, and 
specific research in a university setting.   
Chapter 1 discusses tuberculosis (TB) on a global scale. It uses TB as an example 
of a bacterial infection in dire need of novel antibiotics to treat the infection. The chapter 
brings up some of the reasons for the need of new antibiotics for TB and bacterial 
infections as a whole.  
Chapter 2 discusses the current state of the antibiotic pipeline and the problem 
with decreased investment in antibiotic research and development. It addresses some 
reasons why the pipeline is dry and the historical and current involvement of big pharma 
companies in the R&D of novel antibiotics. Specifically, it emphasizes big pharma’s 
increased investment in lucrative pharmaceutical categories and decreased investment in 
antibiotics.  
Chapter 3 discusses current avenues to address the antibiotic funding issue. The 
chapter is split up into four categories: commercial, non-profit, government, and academia. 
Within those sectors are many avenues that can help and are attempting to alleviate the 
problem.  
Chapter 4 discusses a specific example of attempted antibiotic research in the 
university setting. Specifically, this is research I have done under the direction of Dr. Kateri 
Ahrendt at Regis University. The research is devoted to identifying inhibitors of 
Mycobacterium tuberculosis class IIa fructose-1,6-bisphosphate aldolase (MtFBA). 
The conclusion summarizes my views on the courses of action that should be 
pursued most heavily in attempt to address the problem.  
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CHAPTER ONE-Tuberculosis 
Tuberculosis (TB) is a bacterial disease that affects the world on a global scale. 
One third of the world is infected with latent TB and the disease primarily affects 
developing countries, such as Africa and India. TB is one of many diseases treated with 
antibiotics, and if it goes untreated can kill the host. The current drug regimen 
recommended by the World Health Organization (WHO) involves a six month treatment 
with four different drugs, which if taken correctly cures the patient. However, the lengthy 
treatment can lead to patient compliance issues and the development of drug-resistant 
TB, especially in developing countries where the disease is of greater concern. New TB 
antibiotics are needed in order to decrease the current lengthy treatment and to better 
address the epidemic. 
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TUBERCULOSIS ON A GLOBAL SCALE 
Tuberculosis (TB) is a disease associated with poverty as over 95% of reported 
cases and deaths due to tuberculosis are in middle and low income countries. As 
illustrated in Figure 1.1, sub-Saharan Africa possesses the most new cases per population 
with an average of over 280 cases per 100,000 population in 20131. The high prevalence 
of HIV has caused tuberculosis to rise to epidemic levels in Africa making it the home to 
29% of global TB cases and 34% of TB related deaths2. 
 
 
TB is second only to human immunodeficiency virus (HIV) as the greatest 
worldwide killer caused by a single infectious agent1. The disease accounts for about 9 
million new cases and around 1.5-2 million deaths annually2. One third of the global 
population is infected with latent TB2 and while latent TB is asymptomatic and cannot be 
Figure 1.1.  World Health Organization (WHO) estimated tuberculosis incidence rates as of 2012. 
Adapted from: (1). 
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transmitted, an estimated 10% of these individuals will develop the active form in their 
lifetime1. Persons infected with HIV are 30 times more likely to develop the active disease 
than those without infection1. Although occurring slowly, the rate of new TB cases is 
decreasing each year, providing evidence that the world is making progress towards the 
Millennium Development Goal of halting the spread of TB by 20151. However, TB spread 
was not stopped by 2015 causing the WHO to devise a plan for a post-2015 TB fight to 
further their original goal.  
ANTIBIOTICS 
TB is caused from infection by the bacteria Mycobacterium tuberculosis (Mtb) (also 
known as Tubercle bacillus), thus rendering it one of the many diseases treated with 
antibiotics. Diseases treated with antibiotics pose a substantial threat of developing 
antibiotic resistance. Mtb is a Gram-negative bacteriaA thus the bacteria pose a greater 
risk of developing antibiotic resistance. The Food and Agricultural Organization (FOA) 
defines antibiotics as “drugs of natural or synthetic origin that have the capacity to kill or 
to inhibit the growth of microorganisms”4. However, this definition does not capture the 
true aim of antibiotics. The World Health Organization (WHO) defines antibiotics as a 
“synonym for antibacterials used to treat bacterial infections in both people and animals”5. 
The FOA definition refers to antimicrobials, but the WHO acknowledges the fact that 
antibiotics are reserved to combat bacterial infections in human and animals, rather than 
combatting all diseases caused by microorganisms such as yeast, amoeba, fungi and 
protozoan. In the 1800’s antibiotics referred to anything that killed microorganisms, but 
has since been revised to incorporate the ever changing state of disease.  
Although, antibiotics have successfully treated bacterial infections, bacteria can 
develop resistance to antibiotics, making the diseases even more difficult to control. 
Antibiotic resistance can occur in several ways. One way is when certain bacteria that 
have a natural immunity to the drug and are not killed by the first treatment with the 
antibiotic. The resistant bacterium grows, proliferates and creates a new drug resistant 
bacterial culture6. This type of resistance may be observed due to premature interruption 
                                                          
A Gram-negative bacteria have an additional outer cell membrane composed of phospholipids and 
lipopolysaccharides, as opposed to the single membrane of Gram-positive bacteria3.  Thus, Gram-
negative bacteria are harder to kill.  
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of the antibiotic regimen, thus ineffectively treating the disease and permitting a rise in 
drug-resistant bacteria1. Additionally, bacteria can gain resistance through mutations. In 
this case, bacteria that were once susceptible to antibiotics are no longer susceptible 
because their genetic code is mutated in some aspect that renders the antibiotic 
ineffective6.  
Antibiotic resistance is of great concern as diseases that were once curable by 
common antibiotics may no longer successfully be treated, which threatens the rise of an 
epidemic from a disease that was once easily controlled. In turn, tuberculosis is one such 
disease that has risen to epidemic levels in some areas partially due to the development 
of antibiotic resistance. 
TUBERCULOSIS SPREAD AND EFFECTS 
TB is spread through the air1 rather than the conventional routes of other diseases 
such as shaking hands, kissing, and sharing food or drink7. Once infected, the bacteria 
may remain dormant leading to latent TB, or spread, leading to active TB.  Those with 
suppressed immune systems, such as HIV/AIDS patients, are at a significantly higher risk 
of developing the active disease1.  
Active TB has several symptoms (Figure 1.2) including a bad cough lasting three 
weeks or longer, coughing up blood or phlegm from the lungs, chest pain, weight loss, 
loss of appetite, weakness, fatigue, chills, fever, and night sweats1,7. The symptoms may 
be mild for many months causing individuals to delay treatment potentially infecting 10-15 
people within a year of infection1.  If not treated, TB can be fatal. According to the World 
Health Organization, 2 million people die each year from TB and this number will not 
decrease unless TB control is strengthened1.     
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When infected, the bacteria most often attack the lungs but can attack any part of 
the body7. Pulmonary tuberculosis, affecting the lungs, is the most common form of the 
disease8. Pockets and cavities can form in the lungs, and the damaged areas may bleed 
or get infected with other bacteria and form abscesses9 that lead to the formation of holes 
between airways in the lungs.  
When a person is infected with tuberculosis, their body has a natural response to 
combat the disease. Activated macrophagesB attempt to kill the bacteria and the body 
exhibits delayed-type hypersensitivity (DTH), where the body kills its own tissues so that 
the bacteria may be killed and prevented from replicating and harming the host10. DTH 
tissue damage is essential to control the infection; however, if it occurs in excess it may 
impair organ functions8. In a TB animal disease model, guinea pigs infected with 
tuberculosis died due to the DTH response, presumably because of extensive lung 
                                                          
B Macrophages are white blood cells that serve to fight infections in the body. 
Figure 1.2. Common TB symptoms. Adapted from: Tuberculosis in 
India http://microbewiki.kenyon.edu/index.php/Tuberculosis_in_India 
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damage11. Extensive lung damage can lead to death by suffocation due to insufficient 
oxygen to the host8. Additionally, a rare cause of death in TB infections is a Rasmussen’s 
aneurysm. This is the result of damage to the pulmonary artery by cavitary lesions, causing 
massive bleeding and ultimately death12.  
Additionally, TB can affect other areas of the body including the brain and bones. 
For example, tubercular meningitis, occurring in the menaningal membranes of the brainC, 
causes death due to inflammation of the brain leading to fatal seizures and 
hydrocephalus8,D. ExtrapulmonaryE forms of tuberculosis may affect the bone and are 
associated with significant bone deformations and defects8. Fortunately, tuberculosis is a 
treatable disease and death is avoidable upon proper diagnosis and treatment. 
DIAGNOSTICS 
There are several methods 
used to determine whether or not an 
individual is infected with TB so that 
they may be treated before a fatality 
occurs. The tuberculin skin test 
(also known as the Mantoux test) 
requires a doctor to inject a small 
amount of tuberculin (a protein 
extracted from M. tuberculosis) into 
the skin. Two to three days later the 
doctor looks at the injection site 
which, if infected, may be a raised hard or swollen area with an appearance similar to a 
positive allergy test. The results of the test are determined based on the size of the bump 
(Figure 1.3).  A positive test indicates that the patient has been infected with TB; however, 
                                                          
C It is hypothesized that M. tuberculosis has the ability to breach the blood brain barrier by the 
specialized endothelial cells lining the brain microvasculature, human brain microvascular 
endothelial cells (HBMECs). M. tuberculosis triggers its own uptake into the cells indicating that the 
required conditions may be specific to a particular virulence13. 
D Hydrocephalus is excessive fluid build-up in the brain. 
E Extrapulmonary means outside of lungs. 
Figure 1.3. Tuberculin skin test injection site and 
measurement. Adapted from: (9) 
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this result does not provide information whether or not the disease is in its active or latent 
form7.  
False-positives can occur in the Mantoux test if the patient has received the bacilli 
Calmette-Guerin (BCG) vaccine. The BCG vaccination is most often given to people 
inhabiting countries where TB is a higher threat than in certain developed countries (such 
as the United States). It is reserved for people with very specific requirements including 
children that have previously been ineffectively treated for TB and health care workers 
that take care of a high amount of patients infected with drug-resistant TB14.  
Additionally, TB blood tests are used to determine if a patient has been infected. 
The test, known as the Interferon Gamma Release Assay (IGRA), measures the patient’s 
immune response to Mtb7. A positive result indicates that the person has been infected 
with TB, but like the Mantoux test, it does not provide information concerning the activity 
of the disease.  
Once TB infection has been identified in a patient, further tests are needed to 
determine whether or not the patient has the active form of the disease. The most common 
method is smear microscopy where clinical material is smeared on a glass slide and a 
trained professional identifies Mtb in the material. This method easily identifies highly 
infectious TB cases, is relatively inexpensive, and only takes a few hours to complete. 
However, it has a low case detection at 20-30%, thus requiring multiple repetitions and 
repeat visits by the patient15. Additionally, smear microscopy is unable to distinguish 
between drug-resistant and drug-sensitive TB.  
Bacterial cultures are more sensitive than smear microscopy and successfully 
identify Mtb in over 80% of TB cases15, which provides a more definitive diagnosis16. 
However, this method still has its drawbacks. Visual detection of bacterial colonies is slow 
at 2-6 weeks compared to only a few hours in the smear microscopy method. Additionally, 
the test is expensive and is limited in developing countries that have inadequate access 
to resources15.  
The above methods determine if a patient has active TB; however, none of the 
tests have the ability to identify if the disease exhibits any drug-resistant properties. 
Several tests have been developed that have the potential to determine this, but the tests 
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are still in the beginning stages, thus the timing of the tests and most cost-effective 
diagnostic tools are still unknown15.  Nevertheless, a new two-hour test (Xpert test) that 
has been effective in identifying drug-resistance has been introduced across several 
countries17. The test analyzes TB deoxyribonucleic acid (DNA) for genetic mutations that 
make the bacteria resistance to certain antibiotics16.  
TB CHEMOTHERAPY 
Once a positive test is confirmed, the patient begins treatment. TB chemotherapy 
began with the discovery of streptomycin (SM) in 19442,18 followed by the discovery of 
para-aminosalicylic acid (PAS) in 194619. In 1946 the British Research Medical Council 
performed a randomized clinical trial of SM, proving its efficacy; however, in 1948 (a short 
two years later), SM resistance in pulmonary tuberculosis was observed18,20. Isoniazid 
(INH) was discovered in 1952, due to a 1945 discovery of nicotinamde’s anti-tuberculosis 
activity21. The use of prothionamide (PTH), discovered in 1956, in combination with SM 
was observed to prevent bacterial resistance observed with treatment using only SM, 
giving rise to the important principle of drug combination in TB treatment2. However due 
to issues such as resistance, most of the mentioned drugs are not in the current treatment 
recommendations.  
  
                                                          
F thioacetazone is not commonly used but can replace rifampin when there is a cost issue. 
Common TB drugs used  
First-line (used to treat drug-susceptible 
TB) 
Second-line (used in addition to first-line to 
treat drug-resistant TB 
isoniazid, rifampin, pyrazinamide, ethambutol, 
streptomycin, thioacetazoneF 
amikacin, capreomycin or kanamycin 
Table 1.1. Most common drugs used to treat TB. First-line drugs are used to treat drug-
susceptible TB, the injectable second-line drugs are used to treat drug-resistant TB. 
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Current TB chemotherapy is intensive, requiring six months of treatment with four 
different antibiotics. For drug sensitive TB, the World Health Organization (WHO) 
recommends two months of therapy with isoniazid (INH), rifampin (RIF), pyrazinamide 
(PZA), and ethambutol (EMB) (Table 1.1, Figure 1.4), followed by an additional four 
months of INH and RIF treatment2.  In the United States this treatment costs about $2,000 
per patient, and this regimen has been successful with a 78-95% cure rate1. In low income 
countries where cost is an issue, RIF can be replaced with thioacetazone or EMB, 
lengthening the treatment by two months but providing comparable results2.  
 The four drug 
regimen is used in order to 
prevent drug resistance as 
each drug is designed to act 
on specific bacterial 
populations with different 
metabolic states. This idea 
serves to prevent drug 
resistance and improve 
therapy efficacy2. In most 
bacterial infections a small 
amount of bacteria remain 
after proper treatment and 
the body’s immune system 
is capable of killing the remaining cells. However, the human body often cannot fully 
eradicate the remaining Mtb22 leaving a troublesome persisterG population (dormant 
bacteria that are not initially eradicated with drugs). Mtb resides in a multitude of different 
environments including a highly oxygenated state in the lungs of those infected, a low 
oxygen state in its host (macrophage phagoloysome), a virtually anaerobic state in closed 
                                                          
G It is speculated that Mtb utilizes ManLAM (a TB virulence factor) to activate an anti-inflammatory 
immunosuppressive program by antigen-presenting cells that can modulate T cell responses to maintain 
persistence in the host22. 
Figure 1.4. Drugs used to treat drug-sensitive TB disease. 
From left to right isoniazid, rifampin, pyrazinamide, and 
ethambutol. Streptomycin (not shown) is given by injection. 
Adapted from: 
http://textbookofbacteriology.net/tuberculosis_3.html 
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lesions, and an acidic state during inflammation leading to the production of bacteria with 
different metabolic states2.  
Mtb exhibits four distinct metabolic states, all of which are affected by the different 
TB drugs. explained by one treatment model23. In the model, actively growing cells are 
mainly killed by INH, semi-dormant bacteria in an acidic environment are mainly killed by 
PZA, semi-dormant bacteria demonstrating spurts of active metabolism are preferentially 
killed by RIF, and completely dormant organisms are not killed by drugs, and thus form 
the persister population.  
The presence of dynamic 
bacterial subpopulations, illustrated 
in Figure 1.52, explains the need for 
a two phase chemotherapy. As 
mentioned, the first block of 
treatment involves INH, RIF, PZA, 
and EMB for the first two months 
and a continuation of INH and RIF 
for the following four months. After 
the first two months of treatment 
with all four first-line drugs, actively 
growing bacteria have been killed and now compose the minority of the bacterial 
population2, thus the majority remaining is dormant persister bacteria.  Some of the 
dormant persisting bacteria can revert to actively growing bacteria that can be killed by 
INH and RIF, thus providing a reason for continuing the use of INH and RIF for an 
additional four months2. Similarly, this is the reason that INH is used to treat the 
asymptomatic latent TB. In latent TB some dormant bacteria may revert and become 
active, but INH kills them before they grow and proliferate and cause an active disease 
state. While this therapy provides a clinical cure for the disease some bacteria can remain 
in lesions as persisters, thus leading to a possible relapse2.  
This two phase chemotherapy is designed to decrease the incidence of antibiotic 
resistance; however, issues such as patient compliance can lead to the development of 
resistance. 
  
Figure 1.5. Yin-Yang model of TB life cycle as 
proposed by Zhang. Demonstrates the effect of 
different TB drugs on TB bacterial populations. 
Adapted from: (2) 
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DIRECT OBSERVED TREATMENT SHORT-COURSE (DOTS) 
Because treatment is lengthy, patient compliance issues can arise, rendering 
further treatment ineffective due to the development of antibiotic resistance. One of the 
main causes of antibiotic resistance in TB is premature interruption of treatment1. As such, 
the WHO has developed the direct observed treatment short-course (DOTS) which aims 
to address the patient compliance issue and other issues at the heart of the WHO’s stop 
TB strategy. The strategy aims to dramatically reduce the global TB burden by 2015H and 
support the development of new tools to prevent, detect, and treat TB1. The strategy 
incorporates six components, with the five main components of DOTS including:  
1. Political commitment with increased and sustained financing 
2. Case detection through quality assured bacteriology 
3. Standardized treatment with supervision and patient support 
4. Effective drug supply and management system 
5. A monitoring and evaluation system and impact measurement1.  
The third category on the above list incorporates ideas that aim to help control the 
development of future TB antibiotic resistance by addressing the causes of premature 
treatment interruption. With supervised treatment, patients are more likely to complete the 
full treatment and be cured, leading to a decrease in antibiotic resistance. In some affected 
persons, such as prisoners, drug users, and the mentally ill, the supervision may include 
direct observation of therapy (DOT) where a trained professional administers the drugs 
and watches the patient swallow them24.  If supervision is necessary, it may be carried out 
in a local health-facility, the workplace, the community, or at home1. When DOT is 
unnecessary, supervision is context-specific and given in a patient-sensitive manner that 
aims to ensure cooperation on the part of the providers of medication, support, and the 
patient receiving it1. Support groups can also help with patient adherence, leading to a 
complete treatment regimen. 
                                                          
HA post-2015 action plan has been created as the TB burden was not reduced to the intended 
extent by 2015. 
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As expressed earlier, TB is associated with poverty, propelling the need for proper 
treatment in these areas. DOTS aims to improve access to treatment so that poverty- 
stricken rural areas have greater access to treatment and have the ability to complete the 
full TB treatment regimen. DOTS intends to address the physical, financial, social, and 
cultural barriers that impede adequate TB treatment1. The main barrier to this treatment is 
the prevalence of drug-resistant TB18. Additional barriers include a governmental lack of 
resources, unwillingness to invest in health programs25, and a patient’s lack of monetary 
means to pay for necessary TB treatment. In African regions especially, HIV co-infection 
serves as another barrier compromising the person's immune system and ability to 
eradicate the disease even in the presence of proper treatment18. Further roadblocks 
affecting African countries include declining socioeconomic conditions, populations that 
are at heightened vulnerability, and restraints on human resources affecting the health 
service sector18. In order to combat these barriers the WHO advises actions that include 
expanding treatment outlets in the poorest settings, providing care in closer proximity to 
patients, and offering heavily subsidized or free services1. Unfortunately, some developing 
countries have refrained from employing the advised DOTS course of treatment18.  
DRUG-RESISTANT TB CHEMOTHERAPY 
While chemotherapy using INH (1952), RIF (1957), PZA (1952), and EMB (1962)26 
led to a decline in TB prevalence, strains of TB resistant to these drugs began to emerge 
in the in the 1980s27. There are currently three types of drug-resistant TB strains: multi-
drug resistant TB (MDR-TB, resistant to at least INH and RIF), extensively drug-resistant 
TB (XDR-TB, resistant to INH, RIF, and any one of the fluoroquinolones or second-line 
injectables) (Table 1.1), and the less frequent rifampin-resistant TB (resistant to RIF; 
MDR-TB and XDR-TB fall into this category)1. The incidence of TB and MDR-TB 
decreased from 1993 to 1999, but shortly thereafter the WHO was forced to expand its 
definition of MDR-TB to include XDR-TB27. 
Although the current TB regimen has shown success, Mtb resistance has 
complicated the already lengthy chemotherapy. There are two ways a person can contract 
MDR-TB. The first way is the development of drug-resistance due to previous inadequate 
treatment of drug-susceptible TB. The second way is to contract it from another person 
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infected with the drug-resistant TB1. It is believed that direct transmission is the most 
common way MDR-TB is contracted28. 
The drug regimen for MDR-TB is complex and based on the patient’s individual 
drug resistance profile. The patient undergoes drug susceptibility testing to assess which 
drugs their strain is resistant to. The patient is treated with reserve drugs, including the 
fluoroquinolones (discovered in the 1980s), and any remaining first line drugs that their 
particular strain is not resistant to. Therapy for MDR-TB uses five antibiotics over an 18-
24 month period26, including one injectable, until bacterial cultures test negative29. 
Following the negative result, treatment with a minimum of three drugs is continued for an 
additional 9 months29. The cost of this treatment is very high, ranging from $85,000-
$120,000 (as compared to $2,000 for drug-susceptible TB), rendering it less accessible in 
developing countries. To address these high costs the WHO has proposed the DOTS-plus 
program for observation of MDR-TB treatment29. The program requires drug availability at 
a reasonable cost, a good TB program, and support for drug-resistance monitoring then 
the treatment may be carried out with reasonable cure rates29.   
MDR-TB requires excessive treatment, often lasting for multiple years, and brings 
very serious side effects. Because the current treatment cannot eradicate the persister 
population of bacteria, TB patients are at a higher risk of disease relapse. The main side 
effects include:  
1. Ototoxicity (hearing loss) 
2. Psychiatric disorders 
3. Gastrointestinal effects 
4. Arthralgia (joint pain) and arthritis 
5. Seizure activity 
6. Hepatitis 
7. Rashes 
8. Low white blood cell count 
9. Peripheral neuropathy (numbness, tingling of limbs) 
10. Nephrotoxicity (creatinine serum rise) 
11. Hypothyroidism30.  
Additionally, patients with XDR-TB are at an even higher risk. Their particular strain 
is resistant to the most potent first and second-line drugs. Like patients with MDR-TB, the 
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XDR-TB patient undergoes drug susceptibility testing and is consequently treated with 
additional drugs. These can include drugs not previously used in the area of treatment31, 
and additional Oral Bacteriostatic Second Line Agents (para–aminosalicylic acid, 
cycloserine, terizidone, thionamide, prothionamide)16. However, successful treatment 
lasts for more than 24 months and necessitates aggressive regimens with the highest 
tolerated doses31. The XDR-TB treatment regimen also provides similar side effects as 
MDR-TB treatment.  
Treatment for drug-resistant TB is extremely lengthy and has detrimental side 
effects; however, most individuals with drug susceptible TB are cured with the six month 
regimen, with an estimated 22 million lives saved by the therapy. Even though the 
treatment has shown success, it is lengthy and uses multiple drugs which in conjunction 
with incorrect use of antibiotics, ineffective formulation of drugs, and premature 
interruption of treatment, presents a greater chance of the development of antibiotic 
resistance1. These, along with other reasons, propel the need for novel TB antibiotics. 
Unfortunately, the main discovery engines for these needed drugs are not currently 
keeping up with the present need for antibiotics. 
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CHAPTER 2-Antibiotic Funding 
The current pipeline for novel antibiotics is very limited. There are few new 
chemical entities entering or many novel antibiotics leaving the pipeline. This can partially 
be attributed to big pharma’s decreased investment in antibiotic research and 
development (R&D) in lieu of more lucrative pharmaceutical areas. In the past, big pharma 
has been responsible for developing some of the most successful antibiotics including the 
most profitable Zithromax®. However, these companies are reducing their antibiotic R&D 
efforts. Two of the few remaining big pharma companies with active antibiotic R&D 
programs, Pfizer and AstraZeneca, have recently significantly reduced or abandoned their 
funding for antibiotic R&D. Part of the problem can be attributed to the presence of patents. 
Patents are designed to promote innovation as they grant protection for an invention with 
a promise of return for the investor. But, with competition from generics pharmaceutical 
companies are further pressured into devoting funding into more profitable therapy areas. 
  
20 
 
THE CURRENT STATE OF THE ANTIBIOTIC PIPELINE 
Although, there is a desperate need for novel antibiotics to treat tuberculosis and 
many other infectious diseases, a significant lack of development of new antibiotics is 
leaving the antibiotic pipeline dry1. The antibiotic pipeline includes newly synthesized 
compounds that are still in pre-clinical testing and clinical development2. Generally, pre-
clinical drug testing uses animal models to assess potential harmful effects of the new 
drug. If the animal model does not show any adverse effects, then it may be assumed that 
the drug might be safe for human use. 
The drug then undergoes phase I 
clinical trials in healthy human 
volunteers. The volunteers are given 
the drug in a specified dose for a 
specified amount of time. If they do not 
exhibit adverse effects then the drug 
will be moved on to phase II and phase 
III trials. There is a small line between 
phase II and III trials, but they are both 
reserved for testing on humans afflicted 
with the disease3 (Figure 2.1). These 
late stage trials are used to ensure drug 
efficacy. All potential drugs, whether 
they are simple anti-inflammatories or 
novel antibiotics, are required to enter 
clinical trials. After these trials, the drug 
may finally enter the market with the 
prospect of returning revenue for the 
discovering company.  
The discovery of the 
sulfonamides (ex. pediazole), and β-
lactams, (ex. penicillin), in the 1930s4 initiated the “golden era” of antibiotics that lasted 
until the 1970s5. This age of discovery brought about seven new major classes of 
Figure 2.1. A general outline of clinical trial 
phases. Adapted from: 
http://scienceblog.cancerresearchuk.org/2012/05
/21/international-clinical-trials-day-the-wales-
cancer-trials-unit-goes-global/ 
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antibioticsI, as illustrated in Figure 2.2. These discoveries helped make the rampant 
diseases of the eighteenth and nineteenth centuries appear like a thing of the past7. In 
1967 the Surgeon General stated that “it was time to close the book on infectious 
diseases”8. However, soon after, bacteria started to gain the upper hand. Between the 
1970s and 1999, no new classes of antibiotics were discovered4,5 leading to a discovery 
void known as the “innovative gap”9  (Figure 2.2). 
 
Between 2000 and 2013, only 22 antibiotics were approved by the Food and Drug 
Administration (FDA) for market, averaging less than two new per year5, as illustrated in 
Figure 2.3. Within those include five new classes, three of which (oxazolidinones, 
lipopeptides, and pleuromutilins,) were previously reported or patented before 2000, but 
were marketed after the turn of the century9. Even with the very limited success in recent 
antibiotic R&D, the new classes of antibiotics have significant limitations in their ability to 
only treat Gram-positive bacteria5. Gram-negative antibiotic R&D is of great concern due 
                                                          
I An antibiotic class has a distinct chemical structure6. 
Figure 2.2. Between 1962 and 2000 no new major classes of antibiotics were discovered. This  
lack of development of new antibiotics is known as the “innovative gap”. Adapted from: (4) 
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to increased multi-drug resistance and the leaner antibiotic pipeline for these bacteria 
versus Gram-positive10.  
 
 
 
 
 
 
 
Scientists argue that current antibiotic drug development will not be able to keep 
up with the increasing antibiotic resistance among pathogens11, and according to reports 
by the Infectious Diseases Society of America (IDSA) and the European Centre for 
Disease Control the antibiotic pipeline lacks drugs with greater efficacy over other known 
antibiotics12. The World Health Organization has claimed that the rise in antibiotic 
resistance is one of the greatest threats to humankind4. Since the beginning of antibiotic 
use in the 1940s and 1950s, drug resistance has been present and now affects all major 
classes of antibiotics4. The increasing rise of antibiotic resistance and lack of antibiotics in 
the pipeline is a global health concern. But, antibiotic development has been slow lately 
for a multitude of reasons. 
  
Figure 2.3. New antibacterial agents approved by the United States Food and Drug 
Administration, 1983-2012, in 5 year periods.  Adapted from: (21)  
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THE ISSUE OF ANTIBIOTIC FUNDING 
The shrunken antibiotic pipeline and decreased research and development (R&D) 
towards new antibiotics can largely be attributed to a lack of funding for antibiotic R&D13. 
Big pharma companies have been and are continuously halting funding for research of 
antibiotics in lieu of more lucrative pharmaceuticals, such as antidepressants, cholesterol-
lowering drugs, anti-hypertensive agents, and type 2 diabetes treatments. These drugs all 
require chronic administration5 as opposed to antibiotics that are taken for several days or 
weeks at maximum. This limits the market return of antibiotics as they do not need to be 
as much and are not purchased as frequently as other drugs. Drugs that require chronic 
administration have the potential to be blockbuster drugs, which have peak annual single-
product sales of at least $1 billion10. For example, even the world’s most lucrative 
antibiotic, Pfizer’s Zithromax®J, at one point profited $2 billion annually, which is 
significantly lower than the biggest selling drug of all time, Pfizer’s Lipitor®, which is a 
cholesterol lowering drug. Before its U. S. patent protection expired, Lipitor® brought in 
$9 billion annually14,15. Antibiotics do not create as much revenue for developing 
companies for many reasons. 
Market incentives have always been seen to be a driving factor for antibiotic 
research8. Several factors contribute to the antibiotic market that has little to return to the 
investor. First, like all drugs, after patent expiration generics enter the market and are able 
to take profit from the original developing company. Notably, the 20 year patent life causes 
more generics to be prescribed versus patented drugs which tells industry that even if they 
develop an effective antibiotic it may not be able to make a significant impact in the market. 
Second, in Europe specifically, public health pushes to reserve newer drugs for serious 
cases and treat common infections with old antibiotics. Third, the limited duration of 
antibiotic treatment and the curative nature of the drug (in that it is designed to cure a 
disease rather than alleviate symptoms) increases marketing costs for the antibiotic. 
Fourth, as bacteria develop resistance to the created antibiotic, the antibiotic has a shorter 
lifespan in the market, causing companies that invest billions of dollars into creating the 
                                                          
J Zithromax® is a popular antibiotic because of its desirable dosing. The patient only has to take 
one pill for five-days, as compared to other antibiotics that require 2-4 pills for 10 days. Patients are 
more likely the regimen. In addition, it is used to treat several infections, making it appealing to 
prescribe for doctors. 
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drug to not receive full monetary benefits of their investment. Fifth, correlation between 
the value of the effect of antibiotics does not agree with how much the purchaser pays14. 
For example, ceftaroline fosamil, an antibiotic to treat community-acquired bacterial 
pneumonia16 costs $609 for a one-week course whereas Yervoy®, a melanoma treatment 
costs $120,000 for a 12-week course ($10,000 per week)17. It should be noted that if 
effective, antibiotics serve to continue a patient’s life for many years to come while 
anticancer drugs may only prolong the patient’s life for several months or years14. 
However, the cost of antibiotics is significantly cheaper than anticancer drugs, 
downplaying the effect of the antibiotic and reducing its market value. These factors, along 
with many others, cause antibiotics to have a limited investment return, understandably 
dissuading companies from devoting money into developing antibiotics14. This leads to an 
economic driver that is at odds with the medical and social goals of antibiotics, leading to 
industry abandoning antibiotic R&D10.   
EROOM'S LAW  
The idea of Eroom’s law contributes to a stagnant antibiotic pipeline even further 
than the market and investment perspective. Eroom’s law arises from Moore’s law, in fact 
it is Moore spelled backwards. Moore’s law is an economic idea, based on the observation 
that the number of transistors for computers doubled every two years from 1970 to 201218 
while the costs of production stayed the same or decreased. This brings greater 
functionality for the same cost19. The law presents itself as a forecast for societal economic 
growth and possible improvement of mankind19. However, pharmaceutical R&D has 
coined Eroom’s law as an explanation for the lack of development in drug research. 
Contrary to a doubling of transistors every two years as observed by Moore’s law, Eroom’s 
law has observed a decrease in halves of new drugs in the market every 9 years since 
195018. The law presents the idea that powerful forcesK have been able to outweigh the 
                                                          
K Some of these powerful forces include the better than the Beatles problem, cautious-regulator 
problem, and throw money at it tendency. The better than the Beatles problem says that if people 
still like the Beatle’s music and can download it for free, it will be very difficult to have commercial 
success in the music industry. The producer has to make music that is ‘better than the Beatles’. 
This is similar for pharmaceuticals as previous blockbuster drugs are today’s generics18. The back-
catalogue of pharmaceuticals is increasing, thus presenting a far more complex pharmaceutical 
research and development process, deterring R&D in some areas, and further decreasing the 
economic value of drugs to be discovered18. The cautious-regulator problem says the increasing 
regulations, that are sometimes unnecessary significantly reduce the number of prospective drug 
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Table 2.1. Historical big pharma involvement in antibiotic R&D, after the innovative gap until 
now. Adapted from: (8) 
 
 
scientific, technological, and managerial improvements that have occurred in the past 60 
years18. 
BIG PHARMA DECREASED INVESTMENT 
Historically, large pharmaceutical companies have been responsible for 
developing many of the critical antibiotic agents8. But these companies have been and are 
continuously decreasing investment due to many of the reasons stated above.  The 1960s 
were a very prolific time for the development of antibiotics, with the pharmaceutical 
industry developing the sulfonamides, penicillin, streptomycin, tetracyclines, isoniazid, 
macrolides, glycopeptides, cephalosprins, nalidixic acid and other classes leading up to 
the discovery of rifampin8. As mentioned, the innovative gap followed the 1960s. However, 
the 1990s saw a small resurgence from the pharmaceutical industry with the development 
of Pfizer's Zithromax®, Aventis's Synercid®, and Pharmacia's Zyvox®8 (Table 2.1). The 
introduction of Zyvox® in 2001 was the first new class of antibiotics (oxazolidinones) to 
enter the market since rifampin in the 1960s8.   
 
 
                                                          
candidates. The throw money at it tendency is the tendency to add human resources and other 
resources to R&D, leading to a rise in R&D spending. People then try to reduce the costs of R&D 
which may limit productivity18. 
 
1990 – 50% of US and Japanese large Pharma report that they have halted or 
significantly decreased antibiotic discovery efforts 
1990 – Outbreak of vancomycin-resistant enterococcal infections plus 
increasing methicillin-resistant Staphylococcus aureus — some companies 
return 
1999 – Synercid licensed 
2000 – Roche spins off anti-infective discovery 
2000 – Zyvox, a member of the first new antibiotic class in 35 years, is licensed 
2001/2 – BMS, Lilly and Wyeth halt anti-infective discovery; Glaxo SmithKline 
downsizes anti-infective effort. Aventis announces intention to spin-off their anti-
infective group 
2011 – Pfizer reduces, then abandons antibiotic R&D 
2013 – Astrazeneca reduces antibiotic R&D 
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It appears that industry has 
all but abandoned antibiotic R&D, 
(Table 2.1, Table 2.2).  In 2009 a 
report identified that only five of the 
major pharmaceutical companies 
had active antibiotic discovery 
programs which included Pfizer, 
AstraZeneca, GlaxoSmithKline, 
Novartis, and Merck20. However, 
recently Pfizer and AstraZeneca 
have significantly reduced and/or 
eliminated antibiotic R&D21. At one 
point AstraZeneca, Bayer, GlaxoSmithKline, Lilly, Merck, Ortho McNeil/Johnson & 
Johnson, Pfizer, Roche, Sanofi Aventis, Schering-Plough, and Wyeth were the 
international leaders in anti-infective drug discovery and development, but in recent years 
there have only been 3 new compounds in advanced clinical trials from these companies 
and a small handful in phase II or III clinical trials, as illustrated in Table 2.221. This can 
mainly be attributed to the previously mentioned lack of investment in this type of research 
at these companies13 due to the limited potential market return of antibiotics.   
Table 2.2. Big pharma antibacterial pipeline (anti 
Gram-negative, anti Gram-positive). Adapted from: 
(21) 
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THE MAIN PLAYERS IN ANTIBACTERIALS 
ASTRAZENECA  
AstraZeneca (AZ) (Figure 2.4) 
currently markets six antibioticsL. Recently, 
they have been the leader of the big pharma 
companies in antibiotic research and 
development with their introduction of two antibiotics into late stage trials (Table 2). They 
discovered ceftaroline fosamil; an antibiotic approved for the market in 201021. 
AstraZeneca markets ceftaroline fosamil as Zinforo®, in Europe, and Teflaro®, in United 
States markets. It is used to combat community acquired pneumonia and complicated skin 
and soft tissue infections (cSSI)16,22. The most well-known cSSI is the methicillin-resistant 
Staphylococcus aureus (MRSA) infection4.  
Although AZ has entered the most antibiotics into phase II/III clinical trials and is 
one of the few companies to have active antibiotic discovery programs, in a 2013 report 
AstraZeneca stated their plan to decrease their antibiotic research and development 
programs23. They mentioned an increased focus in three categories: respiratory, 
inflammation and autoimmunity; cardiovascular and metabolic disease; and oncology23. 
At the same time they were to strive to “continue to be active in Infection & Vaccines and 
in Neuroscience, though our investments will be more opportunity-driven”23. 
Not surprisingly, the three categories of main focus are lucrative therapeutic areas.  
AstraZeneca has been successful at synthesizing new antibiotics, but even they intend to 
slow antibiotic R&D as they are still a business with a goal of making money, as stated by 
their chief executive officer, Pascal Soriot:  
“Our vision is clear – to be a global biopharmaceutical company with a focused 
portfolio in core therapy areas, underpinned by distinctive science and a growing 
late-stage pipeline, with sound financials offering attractive returns for investors.”23.  
                                                          
L AstraZeneca currently market six antibiotics which include: Cubicin®, FluMist®, 
Merrem/Meronem®, Synagis ®, and Zinforo®22. 
Figure 2.4. AstraZeneca logo. Adapted 
from: http://www.astrazeneca.com/Home 
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The core therapies in which they invest their money are ones that have a promising 
financial return, such as oncology. Oncological drugs have an estimated value three times 
higher than antibiotics, while musculo-skeletal drugs have upwards of ten times the 
value14. From a business standpoint, this is logical as their narrowed focus should bring in 
better revenue for stock holders due to the development of medicines with high consumer 
costs.  
PFIZER  
 Additionally, Pfizer (Figure 2.5), the world’s largest 
pharmaceutical company that has historically been responsible for 
discovering many antibiotics, including Zithromax®, has all but 
abandoned its antibiotic research and development enterprise. In 
February of 2011, Pfizer announced the reduction in antibiotic 
R&D spending for 2012, thousands of lay-offs for research and 
development personnel, and a transition to China that would 
significantly slow antibiotic research and development24. Anti-infective research was to be 
carried out in Shanghai, China, while shutting down anti-infective research at labs in 
Groton, Connecticut, and Sandwich, UK. 
 The 2011 moves were designed to make up for the profit loss that the company 
received when it lost its patent protection for its biggest selling drug, Lipitor®24. As is 
common with many blockbuster drugs, Lipitor® treats a chronic condition, in this case high 
cholesterol. At its highest point, Lipitor® brought in $13 billion in one year. In 2012, the 
patent for Lipitor® expired causing it to no longer have market exclusivity. This resulted in 
a significant loss of profit for the drug, decreasing sales by a staggering 59% from $9.577 
billion in 2011 to $3.948 billion in 201215. There was an additional 41% decrease from 
2012 to 2013 with Lipitor bringing in $2.315 billion in 2013 (Figure 2.6)25,26. 
 
  
 
 
Figure 2.5. Pfizer logo. 
Adapted from: 
http://www.pfizer.com/ 
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Although Pfizer halted its antibiotic R&D, they continue to sell their previously 
marketed antibiotics, some of which include Zosyn®, Zithromax®, Tygacil®, Sulperazon®, 
Dalacin®, and Unasyn®. In 2012 these antibiotics brought in a meager 3.86% of total 
biopharmaceutical revenue for Pfizer. In 2013 this number dropped to 3.61%M and 3.36%N 
in 2014 during the first three-quarters (Table 2.3, Figure 2.7). These antibiotics are listed 
in Pfizer’s quarterly and annual reportings as they are antibiotics that bring in $50 million 
or more per quarter; however, they still produce little revenue for the company compared 
to other drug classes.  This is a difficult dichotomy as the companies with sufficient capital 
for research are the ones decreasing antibiotic R&D. 
                                                          
M Total Dalacin sales are not accounted for in 2013 and 2014 as only drugs with revenues at 50 
million or above for each quarter. 
N Fourth quarter results were not available, this number represents first three quarters of sales.  
Figure 2.6. Lipitor® sales from 2011 to 2014. 2011 was the last year that Lipitor was under 
United States patent protection. *2014 results are from the first three quarters as fourth quarter 
results were not yet available. Adapted from: (15), (25), and (26). 
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 2012 2013 2014 
(Q1-Q3) 
Total Biopharmaceutical 
revenues 
$51,214  $47,878  $33,625 
Zosyn 484 395 229 
Zithromax 435 387 235 
Tygacil 335 358 241 
Sulperazon 262 309 270 
Dalacin 232 50* 50* 
Unasyn 231 228 106 
Total antibioitc revenue  $1,979   $1,727  $1,131 
% of biopharmaceuical 
revenue 
3.86 3.61 3.36 
Table 2.3. Sales from Pfizer’s major selling antibiotics from 2012 (the year after Lipitor lost its 
exclusivity) to 2014. Dollar values represent millions of dollars. ’Fourth quarter results were not 
yet available, these results are from Q1, Q2, and Q3. *Total Dalacin sales are not accounted for 
as only drugs with revenues at 50 million or above for each quarter are included in quarterly 
reportings. Adapted from: (15), (25), and (26). 
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THE PATENT PROCESS AND THE HUNGER FOR MONEY 
United States patents grant protection rights of the product to the inventor “to 
exclude others from making, using, offering for sale, or selling the invention throughout 
the United States or importing the invention into the United States”27. In the United States 
there are three different types of patents: utility patents grant 20 years of protection from 
the date of grant and are reserved for the discovery or improvement of an object, 
composition of matter etc.; design patents grant 14 years of protection and improve the 
manufacture of said objects; and plant patents grant 20 years of protection and are granted 
to the discoverer of a new plant variety via invention or discovery and subsequent asexual 
reproduction27. For example, the patent that has been discussed in regards to Lipitor is a 
utility patent. 
Figure 2.7 Pfizer’s total biopharmaceutical sales compared to the total sales from Pfizer’s major 
selling antibiotics (Zosyn®, Zithromax®, Tygacil®, Sulperazon®, Dalacin®, and Unasyn®). In 2012, 
antibiotics revenue was 3.86% of total biopharmaceutical sales, 2013 was %3.61 and 2014 (Quarter 
1-Quarter 3) was 3.36%. Adapted from: (15), (25) and (26). 
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"To obtain a patent, an invention must be (1) novel—meaning that it has not been 
published more than a year before the patent application; (2) not obvious; (3) 
useful; and (4) adequately disclosed in the patent application to enable a scientist 
to practice the invention.”28  
The purpose of granting patents is to ensure that the developer receives proper 
financial compensation for their efforts. For drug discovery, this is inherently necessary 
due to the high cost of drug development, particularly due to clinical trials. In order for 
these trials to be worth the financial risk, the final drug should create enough compensation 
to cover the costs, and ideally, help finance future research efforts. When developing a 
drug, companies often start the patent process very early in the development process. 
This is to ensure that a drug is patented and protected when clinical trials are concluded. 
The average time for prosecution of a biotech patent is 4.4 years and the FDA approval 
process requires about 10-12 years of development29. In the United States, a patent for a 
drug lasts 17 years from when the patent was approved, and 20 years from when it was 
submitted to the patent office30, but because companies tend to start the patent process 
early, the patent really only provides on average 12 years of patent protection once the 
drug enters the market. The clinical trial and Food and Drug Administration (FDA) approval 
processes decrease the life of the patent, underscoring the importance of patents in new 
drug discovery31.  
In addition, the 1984 Hatch-Waxman Act (Drug Price Competition and Patent Term 
Restoration Act) further increased the importance of patents, because it decreased the 
time required for a generic drug to enter the market once its name brand competitor lost 
its patent protection. The basic idea of the act works to speed up the process of entering 
generic drugs into the market by allowing generic equivalents to enter the market without 
repeating pre-clinical testing and clinical trials31-33. This helps to introduce cheaper drugs 
for patients sooner, but it causes the developing companies to lose revenue on their drug 
in a shorter time period.  
A patent does not offer endless protection, as it expires after a certain amount of 
time allowing other companies and researchers to reproduce and sell the product. As 
shown in the case with Lipitor, competition from generics significantly lowers a drug's 
profits for a company when a patent ends and the drug loses its exclusivity. Generic drugs 
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generally cost significantly less than their brand name counterparts. In 2011, when Lipitor 
lost its exclusivity, it did not have a significantly lower out of pocket cost than its generic 
competitor, atorvastatin34. This was because in early 2012 only two companies were 
producing and marketing atorvastatin. However, later in 2012 more companies started 
marketing the drug, lowering the costs of the generic drug and decreasing revenue for 
Pfizer. Additionally, when a physician prescribes a drug, he/she does not necessarily do 
so with the patient's finances in mind, meaning if there is a generic option for a drug he/she 
may still prescribe the name brand. The decision of the drug to be distributed is often left 
up to the patient and the pharmacist. If a generic option is available many patients opt for 
it to save money. With an insurance co-pay astoravstatin could be purchased from Cigna 
RX1 for a 3$ copay as compared to $31 for Lipitor34. Additionally, the pharmacist may 
advocate for the generic drug as it often provides higher gross margins for them over 
name-brand competitors35. This being said, when a generic drug is available, the 
consumer will most likely purchase it which ultimately leads to decreased revenue for the 
discovering company.  
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PROMOTING INNOVATION? 
Although patents pave the way for the developing company to receive profit from 
the product they developed, this is not the sole purpose of acquiring a patent. Research 
in the pharmaceutical industry relies heavily on patents35. Pharmaceutical patenting 
revolves around the two related influences: securing competitive market outcomes and 
promoting innovation35. The logic behind patents is that society agrees to give companies 
a temporary monopoly on the product that they develop, allowing them to market the drug 
at high prices, bringing in profit that can be devoted to further research, thus providing 
incentive to innovate36,37. To achieve a solid return when developing a new drug, business 
developers need to be aware of the potential market production. If business developers 
can predict how well their product will do in the market, then they can use this information 
to determine how much "innovative power" they apply to the product to ensure what they 
create has a promising revenue return. 
A competitive market outcome relies heavily on the cost of developing a drug35. 
Even if a pharmaceutical creates sales, if its development is costly companies will be 
dissuaded from devoting time and money to it. A 2003 report estimated that a single drug 
costs $802 million to develop38, which includes preclinical and clinical development. These 
numbers may vary based on the type of drug being developed39,O. A 2007 repeat of the 
2003 study reports an increase in the cost to about $1 billion39, while an additional study40 
reports it just over $1.2 billion. More recent estimates place this value around $1.5 billion41  
(Figure 2.8). With these high costs for drug development it is obvious why antibiotics do 
not receive much attention. If a company looks at the potential market production for an 
antibiotic, profit may seem out of reach, leaving companies to devote innovative power to 
more lucrative pharmaceuticals.  
 
                                                          
O The estimated expected cost of developing an HIV/AIDS drug is $479 million, while the expected 
cost of developing a rheumatoid arthritis drug is $936 million (Adams2006). 
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Although patents are intended to promote innovation, they have caused the 
pharmaceutical industry to use them for profit maximization, limiting innovation towards 
novel antibiotics. The continuing reduction in antibiotic R&D is problematic considering the 
increasing threat of antibiotic resistance. After Pfizer's 2011 moves to limit, and ultimately 
halt, antibiotic R&D, Brad Spellberg, a member of the Infectious Diseases Society of 
America’s (IDSA) Antimicrobial Availability task force made the statement that “the only 
remedy...[is] to create a new economic environment for antibiotic drugs that [restores] the 
financial incentives for R&D.”24. The question now is, is this being done, and if not, what 
other options are available to combat the lack of antibiotic R&D? 
 
  
Figure 2.8. Cost to develop a single drug in years ranging from 1975 to 2012. These costs 
include both research (drug discovery) and development (clinical trials and market approval) 
costs.  Adapted from: (38), (39), (40), and (41). 
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CHAPTER 3-What is Being-Done to Address the Problem? 
Recently Big pharma has decreased its investment in antibiotic research and 
development and limited their spending on clinical trials. A study on the 16,055 antibiotics 
that have gone into clinical trials in the United States from 2000-2013 (1,235 per year) 
found that the majority of antimicrobial studies in the United States are funded by non-
profit organizations (60%), followed by industry (30%) and the federal government (10%)1.  
The decreased investment from big pharma in antibiotic research and 
development is a problem that if not addressed could further exacerbate the antibiotic 
pipeline problem and antibiotic resistance. Fortunately, there are many sectors that are 
devoted to addressing this almost insurmountable problem; specifically: non-profit, 
commercial industry other than traditional big pharma, government, and academia. 
In the commercial sector, small biotech companies have increased their antibiotic 
R&D. This provides big pharma the opportunity to support clinical trials at a decreased 
cost. In the non-profit sector, the Infectious Diseases Society of America (IDSA) has 
started the 10x20’ initiative devoted to developing new systemic antibiotics and the Bill 
and Melinda Gates Family Foundation is devoted to combatting the global TB crisis. In the 
government sector the National Institutes of Health (NIH) devotes significant sums of 
money on supporting antibiotic research and clinical trials; the Food and Drug 
Administration (FDA) advocates for improved non-inferiority trials; and the Centers for 
Disease Control (CDC) created the Tuberculosis Trials Consortium (TBTC) to increase 
clinical trials for TB. In the academic sector, the Tufts Center for the Study of Drug 
Development (CSDD) is devoted the assessing current drug development and finding 
ways to alleviate financial burdens of the process. There are several university labs such 
as UNC-Chapel Hill and Northeastern University devoted to developing and studying 
antibiotics.   
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NON-PROFIT ORGANIZATIONS 
10 x ‘20’ INITIATIVE 
The Infectious Diseases Society of America (IDSA) set a goal of creating a global 
antibiotic R&D enterprise to combat the antibiotic pipeline problem2. In an attempt to 
achieve this, the IDSA has created a global collaboration, endorsed by the American 
Academy of Pediatrics, American Gastroenterological Association, the Trust for America's 
Health, Society for Healthcare Epidemiology of America, Pediatric Infectious Disease 
Society, Michigan Antibiotic Resistance Reduction Coalition, National Foundation for 
Infectious Diseases, and the European Society of Clinical Microbiology and Infectious 
Diseases. 
The goal of the enterprise is to create 10 new safe 
and efficacious, marketable, systemicP antibiotics by 2020, 
otherwise known as the 10 x ’20 initiative (Figure 3.1)2. To be 
successful this initiative requires many feats, but one of the 
main ideas is to include the leaders in global political, 
scientific, industry, economic, intellectual property, policy, 
medical and philanthropic fields2. However, since the IDSA’s 
report in 2009, only two new systemic antibiotic agents have 
been approved, which are telavancin (Theravance), and 
ceftaroline fosamil (AstraZeneca). Of these only ceftaroline fosamilQ has potential to be a 
sought after 10 x ’20 drug5. Although the initiative is a worthy cause, it is very unlikely that 
this goal will be met by 2020. 
                                                          
P Systemic means that the antibiotic affects the entire body when administered. It follows the ADME 
path or Absorption, Distribution, Metabolism, and Excretion. The drug first is absorbed into the 
bloodstream, distributed throughout the body, metabolized and broken down, then metabolites are 
excreted. ADME screening is used to analyze and develop doses for the drug3.  
Q Ceftaroline fosamil has shown efficacy against Staphylococcus aureus (the bacteria responsible 
for MRSA infection) and Enterobacteriaceae5, two of the pathogens that effectively “ESKAPE” the 
effects of current antibiotics4. The ESKAPE pathogens are Enterococcus faecium, Staphylococcus 
aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and 
Enterobacter species4.   
 
Figure 3.1. IDSA 10 x 20' 
initiative logo. Adapted 
from: (2) 
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Despite the slow process of the 10 x ’20 initiative, there has been some recent and 
upcoming success in local antibiotics, specifically for TB. In addition to the two new 
systemic antibiotics previously mentioned, four additional antibiotics, antofloxacin 
(Shanghai Institute of Materia Medica), besifloxacin (Bausch & Lomb), fidaxomicin 
(Optimer Pharmaceuticals), and bedaquiline (Janssen Pharmaceuticals), have been 
approved since 20095. In December of 2012, the partnership between Tibotec, part of 
Janssen Pharmaceuticals, and the Global Alliance for TB drug development led to the 
approval of bedaquiline, a first in class antibiotic and the first new TB treatment in over 40 
years5. There are currently six other potential TB drugs in clinical development, including 
delamanid (phase-III, Otsuka Pharmaceutical), perchlozoneR (complete phase-II/III, JSC 
Pharmasyntez), SQ109  (phase-III, Sequella), PA-824 (phase-II, TB Alliance), sutezolid 
(phase-II, Pfizer) and posizolid (phase-II, AstraZeneca), as well as several others still in 
pre-clinical development6-9. 
THE BILL AND MELINDA GATES FAMILY FOUNDATION 
 The Bill and Melinda Gates Family foundation works with partner organizations to 
tackle some of the world’s most critical problems including poverty, malaria, HIV, and TB. 
Increased funding is needed for proper TB research and development. One of the main 
goals of the Bill and Melinda Gates Family Foundation is to raise these required funds. 
The foundation works with the Global Fund to Fight AIDS and the Tuberculosis and 
Malaria UNITAID in order to reduce the cost of innovative technologies10. The foundation’s 
efforts in the TB epidemic range over many levels. The current TB regimen involves 
several drugsS, and, as mentioned, there are strains of bacteria resistant to these drugs, 
propelling the need for novel TB antibiotics. In addition, TB cannot be effectively treated 
with a single drug, causing the development of new TB drugs to require multiple clinical 
trials for a completely new treatment. The significant time and cost of clinical trials could 
cause this process to take decades10, and the foundation is attempting to help accelerate 
this process. 
“To address this obstacle, we have joined with partners to create the Critical Path 
to TB Drug Regimens (CPTR) initiative, which brings together leading international 
                                                          
R Perchlozone is currently approved in a limited market in Russia. 
S Isoniaizd, Rifampin, Pyrazinamde, and Ethambutol.  
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pharmaceutical companies, public health experts, nongovernmental organizations, 
and U.S. and other regulatory authorities to expedite testing of promising TB drug 
candidates in combination and to identify new regulatory pathways and other 
means of accelerating the drug development process”10. 
 The most direct way of preventing the spread of TB is the development of a 
preventative vaccine. The current BCG vaccine provides limited protection for newborns, 
and no protection for pulmonary TB in adults, which is the form of TB that causes the most 
deaths. A new vaccine, even if partially effective, could help decrease TB incidence, 
according to some projections, up to 52% by 205010. The first candidate vaccine made it 
through phase III clinical trials, but due to its inability to protect infants, it was not marketed. 
Similar to the development of novel TB drugs for treatment, the development of a vaccine 
can take many years; therefore the foundation also aims to discover innovative and 
accelerated approaches to vaccine development10.  
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COMMERCIAL INDUSTRY   
SMALL BUSINESS INVESTMENT-DISCUVA 
The current trend in antibiotic research and development has shifted from large 
pharmaceutical companies towards smaller organizations. Specifically, Discuva (Figure 
3.2), a small biotech company based in Cambridge, United Kingdom, is devoted to the 
idea of “one bug, one drug” antibiotics. In the past, antibiotics have been developed to 
treat many bacterial infections. One example is azithromycin, or commonly Zithromax®, 
which treats multiple infections including skin infections, ear infections, and sexually 
transmitted diseases11. However, due to increased antibiotic resistance these once 
panaceas no longer have the ability to stop all of the bacterial infections they were 
intended for and have become ineffective against Gram-negative bacterial infections. 
There is currently a significant lack of development in new classes of antibiotics which is 
the exact problem that Discuva is addressing. By attempting to develop novel classes of 
antibiotics, or “one drug for one bug”, they eliminate significant risks of antibiotic resistance 
present in multi-target antibiotics12. 
Discuva employs SATIN (Selective Antibiotic Target IdentificatioN) technology to 
identify specific molecular targets and genes that have the potential to cause antibiotic 
resistance and reduce the antibiotic’s efficacy13. In essence researchers can see what the 
compound is doing inside of the bacteria, a process that cannot be obtained with traditional 
biochemical techniquesT. The use of this technology ensures that only compounds that 
                                                          
T Traditional biochemical techniques for identifying drug candidates are serendipity, screening, or 
design. Serendipity is when the target is incubated with the potential drug and it is observed if the 
target lives or dies (such as a bacteria) or if they affected improves (mouse model affected with the 
disease). Screening involves taking a compound that is known to have beneficial effects is modified 
slightly to see if the new compound has different effects. Design involves designing drugs to fit into 
the active site of an enzyme that is identified to be a possible drug target14.   
Figure 3.2. Dicuva. Adapted from: (12) 
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have the potential to make it through clinical trials are taken further into the drug 
development process. This can save significant sums of money by eliminating 
unnecessary clinical trials in addition to decreasing the risk of the development of antibiotic 
resistance15.   
THE INDUSTRY DICHOTOMY 
Although small biotech companies, like Discuva, are adopting more antibiotic R&D, 
they often do not have the financial means for pushing drugs through clinical trials. The 
dichotomy for a proper business model stems from big pharma's investment in lucrative 
therapeutic categories and the lack of capital available for small companies further down 
the line of antibiotic research and development16. Small biotech companies have the 
means to perform the early stage of drug development, however they do not have the 
financial capital to drive potential drugs through phase II/III trials17. 
In the past, and today, small biotech companies have needed support from big 
pharma companies to push their drugs through phase II/III trials. For example, the Boulder, 
Colorado based biotech company Array Biopharma, researches several anticancer drugs. 
Oncology is a lucrative therapeutic area, but the company still requires financial support 
from outside sponsors. Array has several anticancer drugs in clinical trials. The clinical 
trials for binimetnib, a potential thyroid cancer drug, are supported by Novartis. The clinical 
trials for selumetinib, a potential drug for the treatment of several types of cancer, are 
supported by AstraZeneca18.  
Although many small biotech companies do not have the means to support phase 
II/III trials, this may provide big pharma companies with an avenue to make profit at a 
decreased cost. The small biotech companies can synthesize potential drug candidates 
and relieve monetary costs of pre-clinical drug development. This provides big pharma 
with the option of supporting clinical trials for the proposed drug without having to pay for 
the discovery process. Additionally, big pharma has the option of choosing the best drug 
candidate. For example, say there are four small biotech companies that have identified 
potential TB drugs. The supporter of clinical trials has the power to choose which company 
to support for clinical trials by choosing the most promising drug candidate which 
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eliminates the supporter’s cost of early drug-development, decreases the risk of failed 
clinical trials, and offers the potential of an investment return.  
GOVERNMENT 
NATIONAL INSTITUTES OF HEALTH (NIH)  
Of the 16,055 
antimicrobial clinical 
trials in the U.S. from 
2000-2013, 6.5% of 
them were funded by 
the National Institutes 
of Health (NIH)1. The 
NIH is made up of 27 
institutes and centers 
ranging anywhere from 
the National Cancer 
Institute (NCI) to the 
National Institute on 
Aging (NIA)19. The 
institute’s storied 
involvement with 
national health can 
partly be attributed to its long standing existence. The NIH informally started in 1798 when 
John Adams helped establish the Marine Hospital Service. “NIH’s mission is to seek 
fundamental knowledge about the nature and behavior of living systems and the 
application of that knowledge to enhance health, lengthen life, and reduce illness and 
disability”`19 (Figure 3.3). 
 The NIH is working to increase collaboration for the improvement of disease in 
general.  The NIH recently opened the NIH Clinical Center, a premier research hospital, 
to non-government researchers through 3-year renewable research grants up to $500,000 
per year. This allows researchers to collaborate with NIH investigators to work towards 
Figure 3.3. A comic generalization of the NIH’s involvement in 
national health. 
http://theweek.com/cartoons/index/270411/editorial-cartoon-nih-
hysteria-vaccine 
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translating laboratory discoveries to improved diagnosis, prevention, and treatment of 
disease19. 
Almost 80% of the NIH’s funding is awarded through competitive grants. The 
institute invests almost $30.1 billion to American medical research annually. In 2013 they 
devoted $240 million to tuberculosis research, $279 million in 2014, and they project to 
spend $279 million in 2015. Additionally, research on TB vaccinations was $26 million in 
2013, $31 million in 2014, and they project to spend $31 million in 201520. They devoted 
over $5 billion to infectious diseasesU research in 2014. The largest spending area by far 
was clinical research with $10.6 billion devoted to the area (Table 3.1). The increase 
across all mentioned areas is encouraging in regards to addressing antibiotic funding. 
 
Research/Disease 
Areas 
2011 2012 2013 2014  2015 
(Estimated) 
Clinical Research $10,503 $10,951 $10,604 $11,087 $11,132 
Clinical Trials $3,093 $3,208 $3,155 $3,221 $3,233 
Infectious 
Diseases 
$3,883 $3,867 $4,887 $5,002 $5,015 
Tuberculosis $209 $218 $240 $279 $279 
Tuberculosis 
Vaccine 
$17 $21 $26 $31 $31 
 
  
                                                          
U Infectious diseases include any disease caused by a microorganism such as a bacteria, fungi, or 
parasite.  
Table 3.1. NIH Categorical spending in different research areas from 2010-2015. Monetary values 
are in millions of dollars. Adapted from: (20) 
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OTHER GOVERNMENT AGENICES 
Less than 1% of the 16,055 antimicrobial studies were funded by government 
agencies besides the NIH. One important agency is the Food and Drug administration 
(FDA) and another that specifically supports clinical trials is the Centers for Disease 
Control and Prevention25. 
FOOD AND DRUG ADMINISTRATION 
The FDA is the government agency that ultimately approves drugs to enter the 
market. The FDA requires that trials include primary safety and efficacy endpoints as 
clinical studies “form the basis for FDA’s finding that a [drug or device] is safe and effective 
for its intended use”21. In addition, it provides guidance and regulations for clinical trials. 
Specifically, in 2010, the FDA proposed further guidelines for antibacterial non-inferiority 
(NI) trials to further support drug approval. Non-inferiority trials (as opposed to superiority 
trials, which use placebos to observe efficacy of the new treatment) are intended to show 
that the new treatment is not worse than the control treatment (the previously used 
treatment for the indicated condition)22. NI trials can be used in cases where there is 
resistance, as it will demonstrate that the new treatment has better efficacy over drug-
resistant bacteria than the standard treatment. One of the reasons that the FDA is 
addressing NI trials is because of the ethical issues involved in superiority trials. As 
mentioned superiority trials involve the use of placebo in comparison to the new treatment.  
When a person signs up for a clinical trial they expect to receive the best therapeutic 
method possible23. But, in superiority trials some of the participants receive a placebo, 
thus they receive no treatment. In a trial for a cholesterol drug this may not be as much of 
an issue as the affliction is not immediately life-threatening. However, if a cancer patient 
enters a clinical trial they expect to receive at least some form of treatment. In a life-
threatening disease this is an issue as a lack of treatment could be detrimental to the 
patient’s health and life.  
 The FDA suggests that the sponsor of the trial uses an active-controlled NI trial 
design to consider the potential treatment effect of the control treatment24. This can be 
achieved from analyzing previously conducted trials of the control treatment. This is to 
ensure there is proper control and efficacy endpoints from previous trials to determine the 
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treatment effect size (which measures the magnitude or size of an effect, or the effect of 
the treatment) for the newly proposed NI trial. Additionally, the FDA suggests that the 
sponsors should re-evaluate current and ongoing NI trials on the scientific basis for the 
treatment effect size of the control. After evaluation, the approval application should be 
amended to reflect these findings. However, if the reevaluation does not provide 
necessary scientific basis then FDA commitments may no longer be valid24.  
CENTER FOR DISEASES CONTROL TUBERCULOSIS TRIALS CONSORTIUM  
The CDC’s slogan “CDC 24/7” (Figure 3.4) 
tells people that “CDC is the nation's health 
protection agency, working 24/7 to protect America 
from health and safety threats, both foreign and 
domestic. CDC increases the health security of our 
nation”25. The CDC aims to protect the nation from 
health threats, from simple measures like the 
prevention of a common cold, to the tuberculosis 
epidemic, and the recent Ebola outbreak in West Africa25. Specifically, in 1960 the U.S. 
Public Health Services transferred its TB control and research program to the CDC. The 
1980’s saw a decline in TB, and consequently a decline in funding for TB. In response, 
the CDC Tuberculosis Trials Consortium (TBTC) was officially created in 1997 to increase 
clinical trials for TB. In the current decade (2010-2020) the TBTC aims to move study sites 
form the United States to international locations to address the global prevalence of the 
disease26. The TBTC has enrolled more than 12,000 patients and volunteers in the past 
15 years, and has an annual budget of $11 million annually. The TBTC is currently 
conducting a trial for an ultra-short treatment of latent TB, and has begun the first clinical 
trial for patients with MDR-TB. According to the CDC “the late pipeline of new anti-TB drug 
candidates is the most promising in 40 years, and advances in TB clinical trials science 
have fostered the progress of these agents”26. 
  
Figure 3.4. Centers for Disease 
Control and Protection’s (CDC) 
slogan, CDC 24/7. Adapted from: 
(25) 
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ACADEMIA  
According to the CDC “developing new TB treatment and prevention strategies 
depends upon collaboration among academic, private sector and government researchers 
and non-governmental organizations”26. This need for collaboration is not limited to TB 
and is relevant for all antibiotic R&D. Specifically, universities can play a role in antibiotic 
R&D. 
TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT 
  The Tufts Center for the Study of 
Drug Development (CSDD) is an 
independent, academic, non-profit 
research group at Tufts University in 
Boston, Massachusetts27. Their mission is 
to “develop strategic information to help 
drug developers, regulators, and policy 
makers improve the quality and efficiency 
of pharmaceutical and biopharmaceutical 
development, review, and utilization”27. In 
2013 they held a Senior Leadership 
Roundtable (Figure 3.5) to discuss the 
adoption and impact of adaptive clinical 
trialV design28. Based on the results of the 
roundtable, simple adaptive designs are 
currently being used in 20% of clinical trials and this number is expected to continue to 
increase28. According to the Tufts CSDD the main prospect in aiding antibiotic 
development efforts is for developers to cut extraneous costs.  Clinical trials are the most 
cost intensive portion of developing drugs. They run hundreds of millions of dollars29 
making clinical trials a strong area of interest in decreasing costs.   
                                                          
V Adaptive clinical trials are preplanned adaptations — generated through the use of trial 
simulations and scenario planning — of one or more specified clinical trial design elements that are 
modified and adjusted while the trial is underway based on an analysis of interim data29. 
Figure 3.5. The Tufts CSDD Senior 
Leadership Roundtable brief cover art. 
Adapted from: (28).  
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Only about one in one-thousand compounds discovered in pre-clinical drug-
discovery will make it all the way through the FDA approval process and enter the market 
as a drug30. Drugs that fail to make it through clinical trials cause the cost of clinical trials 
and drug development to increase significantly. In order to alleviate some financial burden, 
studies involving compounds that will not make it through clinical trials can be terminated 
early. The Tufts CSDD estimates that early termination of studies due to uselessness and 
sample size re-estimationW could save sponsor organizations $100-$200 million 
annually28. One company present at the roundtable reported saving $70 million by 
implementing simple adaptive clinical trial designs28.  
Additionally, using adaptive clinical trial designs for phase II/III dose response 
assessments (these serve to assess harmful side effects of treatment in response to dose) 
are expected to improve late stage success rates. Regulatory agencies see this as the 
most promising benefit from the adaptive clinical trial design.  
Industry has devoted a significant amount of attention to the overall improvement 
of quality and efficiency of clinical trials, which coupled with adaptive clinical trial designs, 
shows promise in improving overall R&D28. 
UNIVERSITY RESEARCH 
NORTHEASTERN UNIVERSITY: ANTIMICROBIAL DISCOVERY CENTER 
 The Antimicrobial Discovery Center (ADC), headed by Dr. Kim Lewis, is a 
molecular microbiology research group at Northeastern University that studies bacterial 
persister cells, drug discovery, unculturable microorganisms, and Mycobacterium 
tuberculosis31. Specifically, the ADC’s work in regards to Mtb involves the study of the 
mechanism of persister bacteria. Persisters are dormant bacteria that remain in the host 
and are tolerant to antibiotics31.  The ADC is working on the discovery of sterilizing 
antibiotics, which completely eradicate all of the bacteria in a bacterial infection, including 
persisters. On this topic specifically, they collaborate with scientists from the small biotech 
companies NovoBiotic and Arietis31.  
                                                          
W Sample size re-estimation is adjusting the sample size in a clinical trial based on interim data to 
ensure that the sample size is large enough to accurately assess a drug’s efficacy32. 
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UNIVERSITY OF NORTH CAROLINA-CHAPEL HILL: MEDICINAL CHEMISTRY 
The University of North Carolina-Chapel Hill Eshelman School of Pharmacy has a 
division in chemical biology and medicinal chemistry33. Specifically Dr. Harold Kohn’s lab 
focuses on bacterial infections. Their lab discovered bycyclomycin, an antibiotic effective 
against Gram-negative bacteria, specifically Escherichia coli. Bycyclomycin acts on the 
rho transcription termination factor, an essential enzyme in E. coli. The lab is now 
attempting to identify the exact mechanism of bycyclomycin, and the rho enzyme in order 
to allow drug design to occur on a less empirical basis34. 
Additionally, the Kohn lab identifies that resistance to conventional antibiotics, such 
as those for TB, is an unmet challenge. Therefore, they are currently pursuing research 
towards the identification of novel TB antibiotics. They have identified metal chelatingX, 
pathogen specific inhibitors for Mycobacterium tuberculosis and have information 
regarding the target site for the compounds34. These type of inhibitors are currently of 
great interest in the search for novel TB antibiotics.  
Academia is an area that could aid in antibiotic research and development efforts. 
The Tufts CSDD’s aim is to help researchers improve efficiency in developing drugs while 
the ADC and Kohn’s lab at UNC are devoted to laboratory research on antibiotics.   
Chemical industry relies on the principle “time is money”. This is part of the reason that 
they have limited investment in antibiotic R&D. Although the patent process, rigor of 
industry, and prospect of monetary return aims to promote innovation, innovation is often 
pushed aside. However, academic laboratory research provides a resource where 
innovation is at the forefront and researchers are free to devote time and resources to 
antibiotic research development.  
  
                                                          
X Metal chelating refers to compounds that have the ability to attach to positively charged metals, 
binding to the area where the metal is situated.  
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CHAPTER 4- Synthesis of potential Mycobacterium 
tuberculosis class IIa fructose-1,6-bisphosphate aldolase 
inhibitors 
This chapter describes a project I worked on from August 2013 to May 2014 
directed towards the identification of inhibitors of Mycobacterium tuberculosis class IIa 
fructose-1,6-bisphosphate aldolase (MtFBA), an essential enzyme in Mycobacterium 
tuberculosis. This enzyme serves as a potential target for novel TB therapeutics. In 
2010 a collaboration was initiated between Dr. Kateri Ahrendt of Regis University, and 
Dr. Scott Pegan of the University of Denver (now at the University of Georgia). Later, 
Dr. Mary Jackson of Colorado State University joined the group. They have worked on 
a collaborative research project in identifying MtFBA inhibitors. Dr. Ahrendt’s lab 
synthesizes potential inhibitors, Dr. Pegan’s lab tests synthesized compounds for 
enzymatic activity, while Dr. Jackson’s lab tests for cellular activity. This research aims 
to identify scaffolds that could serve as potential antibiotics to combat the TB epidemic. 
While working in Dr. Ahrendt’s lab, I played a role in the synthesis of two sulfonamide 
containing compounds. Several Regis University students have been involved in the 
MtFBA project including; Alex Moauro, Nicholas Stephanus, Marina Pschichenko, 
Patrick Serrano, Pablo Cabrera, and Christian Ghincea. I would also like to 
acknowledge the Regis University Chemistry Department for access to laboratory 
facilities, equipment, chemicals and supplies, the Regis University Dayton Memorial 
Library for access to scientific databases and electronic journal subscriptions, the 
Regis University Research and Scholarship Council for financial support, and the 
Colorado Center for Drug Discovery for financial support. 
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INTRODUCTION 
Tuberculosis is currently second to HIV as the greatest killer due to a single 
infectious agent1. Approximately one third of the global population is infected with 
latent TB2 and approximately 10% of these individuals will develop the active disease 
in their lifetime1. The current TB chemotherapy, recommended by the World Health 
Organization, involves four drugs over a six month period. Isoniazid (INH), Rifampin 
(RIF), Pyrazinamide (PZA), and Ethambutol (EMB) are taken for two months followed 
by a continuation of INH and RIF for an additional four months2. The lengthy treatment 
leads to patient compliance issues and the development of drug resistant TB. This 
includes MDR-TB, resistant to at least INH and RIF, and XDR-TB resistant to INH and 
RIF and additional potent TB antibiotics1,3. 
In December 2012, bedaquiline, a first in class antibiotic and the first new TB 
treatment in over 40 years, was approved by the FDA4. There are currently six other 
potential TB drugs in clinical development, including delamanid (phase-III), 
perchlozone (complete phase-II/III), SQ109 (phase-III), PA-824 (phase-II), sutezolid 
(phase-II) and posizolid (phase-II), as well as several others still in pre-clinical 
development4 (Table 4.1). However, these recent TB antibiotic successes do not have 
the ability of eradicating the disease as they do not significantly decrease the current 
length of treatment, thus propelling the need for the discovery of new TB antibiotics. 
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Name of Drug Structure Phase of 
Development 
Bedaquiline 
 
Approved 
Delaminid 
 
Phase II 
Perchlozone 
 
Complete 
phase II/III 
SQ109 
 
Phase III 
PA-824 
 
Phase II 
Sutezolid 
 
Phase II 
Posizolid 
 
Phase II 
Table 4.1. Current potential tuberculosis drug candidates and their respective clinical trial 
phase of development. Adapted from: (4) 
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 One potential TB therapeutic target is Mycobacterium tuberculosis class IIa 
fructose-1,6-bisphosphate aldolase (MtFBA). Fructose-1,6-bisphosphate aldolase 
(FBA) is an essential enzyme present in most organisms, including animals, plants, 
fungi, and bacteria. The enzyme catalyzes the reversible aldol condensation of 
glyceraldehyde-3-phosphate (G3P) and dihydroxyacetone phosphate (DHAP) to 
fructose-1,6-bisphosphate (FBP) (Figure 4.1) in glycolysis and gluconeogenesis5,6,7. 
Glycolysis and gluconeogenesis are the essential carbohydrate break down and build 
up pathways of the cell and are essential for cellular survival, thus inhibition of an 
essential enzyme in either pathway has the potential to kill the cell. Knockout studies8 
have shown that cells cannot survive without FBA.  
 
 
  
While FBA is a ubiquitous enzyme, bacterial FBA is distinctively different than 
human FBA in both protein structure and mechanism of catalysis5,6,9,10 providing the 
opportunity for selective inhibition of bacterial FBA. Class I FBAs, present in humans 
and mammals, catalyze the aldol condensation using a lysine residue and Schiff base 
formation, whereas class II FBAs, present in bacteria, catalyze the reaction by 
stabilization of the hydroxyenolate intermediate with Zinc (II) and sodium ions (Figure 
4.2)5,6. Because of the distinct structure and mechanism of catalysis, class II FBAs 
have the potential to serve as antimicrobial targets as they can potentially be 
selectively inhibited over human class I FBA. 
fructose-1,6-
bisphosphate (FBP) 
glyceraldehyde-3-
phosphate (G3P) 
dihydroxyacetone 
phosphate (DHAP) 
fructose-1,6-bisphosphate (FBP) 
Figure 4.1. Reversible aldol condensation of G3P and DHAP to FBP catalyze by MtFBA. Adapted 
from: (5). 
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Previously reported phosphate containing FBA inhibitors have shown 
activity in bacterial cultures (Table 4.1). The most extensively studied 
MtFBA inhibitor is phosphoglycolohydroxamic acid (PGH, Figure 4.3) 
which mimics the FBA enolate substrate, DHAP (Figure 4.1). However, 
the hydroxamic acid poses potential hazardous side effects9 and due to 
the similarity in structure it shares with DHAP, it lacks selectivity for class 
II over class I FBAs. Furthermore, PGH lacks the necessary physiological properties for 
drug development5. Specifically, the highly charged phosphate group prevents cell 
permeability and is easily hydrolyzed within the cell.  However, removal of the phosphate 
group leads to a loss of enzyme inhibition (Table 4.2). As such, novel MtFBA inhibitors 
may be able to overcome some of these limitations. 
  
Figure 4.2. MtFBA and other 
class II FBAs use Zinc (II) and 
sodium ions to stabilize the 
enolate intermediate. Adapted 
from: (5). 
Figure 4.3. PGH 
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Compound Bacteria IC50 Citation 
 
Mtb 13nM 11. Daher 
2010 
 
Giardia 15µM 12. Mariano 
2011 
 
E. coli 100µM 13. Blonski 
2005 
 
Mtb 2nM 14. Lewis 
1973 
 
 Inactive at 
1mM* 
 
 
To identify potential MtFBA inhibitors, we are using a fragment based approach. 
In this approach, a range of small Zinc (II) chelating molecules are screened at high 
concentration to assess the extent of MtFBA inhibition. The initial compounds are 
readily available, either through commercial search or straightforward synthesis. 
Compounds with highly charged functional groups, such as phosphates, are avoided 
to facilitate cell permeability and bioavailability. The data from initial screens is then 
used to design subsequent target compounds15. 
  
  
Table 4.2.  IC50 of several phosphate containing inhibitors. The IC50 measures the  concentration 
of a drug where the enzyme’s activity is cut in half. *demonstrates inactivity of compounds 
without the phosphate group. 
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Before I joined the research project, using the fragment based 
approach, the group identified commercially available 8-
hydroxyqunoline-2-carboxylic acid (HCA, Figure 4.4) as a 10 µM 
inhibitor of MtFBAY. 
 A significant portion of the fragment based approach involves identifying metal 
chelating groups. The most common metal chelating groups are hydroxamic acids, 
carboxylic acids, and sulfonamides15 (Figure 4.5). As mentioned, charged phosphate 
groups hinder the cell permeability of the compound. Thus, the ideal metal chelating 
inhibitor of class II FBAs is one that exists in its neutral from to an appreciable extent 
outside of the cell, allowing entry and permeability of the cell membrane.  Once in the 
cell, the compound should be able to adopt a negative charged state, facilitating 
enzyme interaction.  
 
 
 
 
We decided to synthesize sulfonamide containing compounds because of their 
ability to chelate Zinc (II) ions when charged. Sulfonamides have an acid dissociation 
constantZ that may allow the compound to serve as a negatively charged Zinc (II) 
chelater at physiological pH16,17. Importantly an equilibrium exists between the neutral 
and charged state; the acid dissociation constant is a measure of this equilibrium. The 
sulfonamide acid dissociation constant is at a value where the compound has a 
significant neutral population outside of the cell allowing cellular entry. Then once 
inside the cell, the sulfonamide proton (H+) can be removed creating a negatively 
charged nitrogen that may serve to chelate with Zinc (II). Compounds with 
                                                          
Y A 10µM inhibitor indicates that the IC50 (half maximal inhibitory concentration) of the compound is when 
the compound is present in a 10µM concentration. The IC50 is the concentration of inhibitor that decreases 
and enzyme’s maximum velocity by one half.  
Z The acid dissociation constant of an acid. The lower the number the more easily the compound releases a 
hydrogen atom and becomes negatively charged. 
Figure 4.4. HCA 
Figure 4.5. Common metal chelating functional groups 
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sulfonamides have shown increased extraction selectivity for Zinc (II) ions over other 
metal ions in solution16. Additionally, the most widely used probes for cellular Zinc (II) 
are aryl-sulfonamides of 8-aminoqunoline18 demonstrating the ability of these 
compounds to permeate the cellular membrane.  This led us to synthesize aryl-
sulfonamide compounds that have the potential to chelate Zinc (II) and have cellular 
membrane transport.  
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RESULTS 
We successfully synthesized two bridged biaryl-sulfonamide compounds 
(KAAI040, KAAI048) (Figures 4.6, 4.7) via multi-step syntheses (Schemes 4.1, 4.2). 
Each step in the overall synthesis was verified with proton nuclear magnetic resonance 
(NMR) and thin layer chromatography (TLC). (The detailed experimental procedure is 
addressed in the later experimental section.) The final target compounds and 
intermediates in the multi-step syntheses were sent to Dr. Pegan at the University of 
Denver to assess MtFBA inhibition. The compounds were tested in a fluorescence 
assay. The inhibition results are presented in Table 4.3.  
 
 
 
   
 
 
KAAI048                                                            KAAI040                                                            
Figure 4.6. Final target compounds for MtFBA inhibition, KAAI040 and KAAI048 
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Scheme 4.1. Synthesis of KAAI040. The nitro group on KAAI029 was reduced using standard 
reduction methods. KAAI035 was globally sulfonylated with excess sulfonyl chloride. The 
sulfonyls on KAAI038 were selectively cleaved under basic conditions, followed by acid workup, 
to yield the resulting sulfonamide, KAAI040. 
Scheme 4.2. Synthesis of KAAI048.  The nitro group on KAAI028 was reduced using Zinc and 
acetic acid. KAAI044 was globally sulfonylated with excess sulfonyl chloride. The sulfonyls on 
KAAI046 were selectively cleaved under basic conditions, followed by acid workup, to yield the 
resulting sulfonamide, KAAI048. 
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ID Structure Formula % inhibition at 25µM in 
fluorescence assay 
KAAI048 
 
 
 
C13H13NO3S2 
 
 
5.50±0.30 
KAAI046 
 
 
 
C15H17NO7S4 
 
 
6.90±0.10 
KAAI044 
 
 
C12H11NOS 
 
7.80±0.60 
KAAI040 
 
 
 
C13H13NO4S 
 
 
5.50±0.50 
KAAI038 
 
 
 
C15H17NO8S3 
 
 
5.30±1.70 
KAAI035 
 
 
C12H11NO2 
 
7.00±0.20 
KAAI029 
 
 
C12H9NO4 
 
9.30±5.20 
KAAI028 
 
 
C12H9NO3S 
 
6.00±0.04 
Table 4.3. Percent inhibition of MtFBA at 25µM in fluorescence assay. Inhibitors were 
tested for inhibition at a concentration of at 25µM. The assay provides a fluorescent 
signal corresponding with the percent inhibition of the compound on the enzyme. 
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Unfortunately, none of the compounds provided significant MtFBA inhibition (Table 
4.3). Interestingly the highest percent inhibition came from KAAI029 (9.30 ± 5.20), an 
early precursor in the synthesis. But with the significant standard deviation, the highest 
inhibition may be KAAI044 (7.80 ± 0.60), a precursor aryl-amine. Neither of these 
compounds were the final sulfonamide containing compounds, but rather, 
intermediates in the respective syntheses. 
CONCLUSION 
The sulfonamide containing compounds, KAAI048 and KAAI040, do not provide 
sufficient inhibition of MtFBA to be considered as potential therapeutic agents. Thus, 
biaryl-sulfonamides may not be good scaffolds for MtFBA inhibition. Alternatively, 
other unique scaffolds will be explored. For example, HCA has been identified as an 
MtFBA inhibitor10 thus future compounds may be modeled after HCA. 
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EXPERIMENTAL 
Preparation of potential MtFBA inhibitors 
Proton NMR spectra were recorded at 60 MHz. 
Preparation of KAAI040 (Scheme 4.1) 
 
 
  
 
 
 
 
 
 
 
  
Scheme 4.1. Synthesis of KAAI040 via nitro reduction, sulfonylation, and hydrolysis.  
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KAAI035 from KAAI029∆ (Scheme 4.3). Nitrogen gas was blown over a solution of 
KAAI029 (2g, 8.65mmol) in 43mL of ethanol. Water (~3mL) was added to obtain a 
0.2M solution. 2% weight Pd/C (0.9204g, 0.433mmol) was added to the flask followed 
by excess hydrogen gas. The solution stirred for 24 hours. KAAI035: 48.5% yield. H1 
NMR (60 MHz, CDCl3): δ 7.074-6.708 (8H, mult.), 4.8-4.3 (1H, broad sing.).  
 
∆KAAI029 was obtained from Dr. Kateri Ahrendt (Regis University). Synthesized via 
nucleophilic aromatic substitution. (Scheme 4.4) H1 NMR (60 MHz, CDCl3): δ 7.6-6.8 
(4 H, mult.) 
 
 
 
 
 
  
Scheme 4.4. Synthesis of KAAI029 via nucleophillic aromatic substitution. 
 
Scheme 4.3. Nitro reduction of KAAI029 to yield an amine KAAI035. 
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KAAI035 from KAAI038 (Scheme 4.5). To a suspension of KAAI035 (0.5g, 
2.48mmol) in CH2Cl2 (~10mL, ~0.25M), NEt3 (~1.12mL, 8.2mmol) was added. The 
resulting solution was cooled to 0oC. Mesylchloride (0.6mL, 7.75mmol) was added 
dropwise. Within 1-2 min a white precipitate started to form, presumably NEt3∙HCl salt. 
TLC taken at 5 minutes (30% Ethyl Acetate/Hexanes) was streaky but showed no 
ninhydrin stain suggesting no remaining Ar-NH2. The mixture was stirred for 2 days. 
The resulting suspension was filtered, extracted using dichloromethane and water, 
and concentrated using rotary evaporation. KAAI038: 19.5 %yield H1 NMR (60 MHz, 
CDCl3): δ 7.5-7.0 (8H, mult.), 3.479 (6H, sing.), 3.163 (3H, sing.) 
 
 
  
Scheme 4.5.  Global sulfonylation of KAAI035 to yield KAAI038 
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KAAI040 form KAAI038 (Scheme 4.6). To a solution of KAAI038 (0.5g, 1.15mmol) in 
methanol (~4mL, ~0.3M), sodium hydroxide (~4mL, ~0.3M) was added and stirred at 
60oC for 24 hours. Hydrochloric acid (~4mL, 0.3M) was added to neutralize the base 
and protonate the product. The remaining methanol was boiled off and the resulting 
sticky residue was extracted in 40 ml CH2Cl2. The organic layer was washed with brine 
and dried with sodium sulfate, concentrated, and washed with diethyl ether three 
times. The residue remained as an oil and ~2mL CH2Cl2 was added and let evaporate 
to obtain the product. KAAI040: 86% yield (0.275g product, 0.985mmol). H1 NMR (60 
MHz, CDCl3): δ 7.256-6.812 (7H, mult.), 3.793 (1H, sing.), 3.364 (1H, sing.), 3.067 
(3H, sing.), 2.941 
 (1H, sing.). Not completely pure. No starting material inferred by the upfield shift of 
aromatic hydrogens. Possible other sulfonylations. 
  
Scheme 4.6. Selective sulfonyl cleavage of KAAI038 with base followed by 
acidic workup to yield KAAI040. 
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Preparation of KAAI048 (Scheme 4.2) 
 
 
 
 
  
Scheme 4.2. Synthesis of KAAI040 via nitro reduction, sulfonylation and hydrolysis. 
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KAAI044 from KAAI028∆ (Scheme 4.7). To a slurry of Zinc dust* (1.99g, 31mmol) in 
30 mL of 95% alcohol (85% ethanol) and acetic acid (7mL) at 0oC, KAAI028 (1.5g, 
6.1mmol) was added. The slurry was heated and stirred at 60oC for 8 hours. The 
resulting product was filtered with celite and washed with 95% alcohol. The resulting 
solution was concentrated and an orange solid was obtained. The solid was then 
extracted using CH2Cl2 and dried using sodium sulfate. The solution was then 
concentrated and an orange solid was collected. KAAI044. 90%yield: (1.2g) TLC (20% 
EtOAc/Hexanes) after 4 hours of stirring was visible with ninhydrin indicating Ar-NH2 
formation. H1 NMR (60 MHz, CDCl3): δ 7.520-6.678 (8H, mult.) 
*Reduction with Pd/C did not proceed presumably due to the sulfur poisoning catalyst. 
Modified procedure from (19). 
∆ KAAI028 was obtained from Dr. Kateri Ahrendt. Synthesized via nucleophilic 
aromatic substitution (Scheme 4.8). H1 NMR (60 MHz, CDCl3): δ 8.216 (1H, mult.), 
7.518-6.869 (8H, mult.), 6.291 (1H, sing.) 
 
 
 
  Scheme 4.8. Synthesis of KAAI028 via nucleophillic aromatic substitution. 
 
Scheme 4.7. Nitro reduction of KAAI028 to yield an amine, KAAI044 
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KAAI046 from KAAI044 (Scheme 4.9). To a solution of KAAI044 (0.5g, 2.30mmol) in 
CH2Cl2 (12mL, ~0.25M) NEt3  (1.4mL, 10.1mmol) was added. The solution was cooled 
to 0oC. Mesylchloride (0.75mL, 9.66mmol) was added to the solution. After about two 
minutes a precipitate started to form, presumably NEt3∙HCl and other salts. TLC (20% 
EtOAc/Hexanes) after 5 minutes of stirring at room temperature was streaky and 
showed no ninhydrin spots assuming no Ar-NH2 remaining. The resulting solution was 
concentrated and a brown solid was obtained. KAAI046. 96%yield: H1 NMR (60 MHz, 
CDCl3): δ 7.570-7.185 (8H, mult.), 3.53 (5H, sing.), 3.181 (3H, sing.) 
  
Scheme 4.9.  Global sulfonylation of KAAI044 to yield KAAI046. 
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KAAI048 from KAAI046 (Scheme 4.10). To a suspension of KAAI046 (0.5g, 
1.1mmol) in 4mL 95% alcohol (85% ethanol) 4mL aqueous NaOH (0.193g, 4.3mmol) 
was added. The resulting suspension was heated and stirred at 60oC for 12 hours. 3M 
HCl was added to neutralize the base and protonate the product. The product was 
extracted with CH2Cl2 and water. The solution was concentrated and a brown oil was 
recovered. Trituration provided ~10mg of solid. (NMR of solid was too dilute to 
determine if desired product). KAAI048. 75% yield. H1 NMR(oil) (60 MHz, CDCl3): δ 
8.14-6.17 (8H, mult.), 3.91 (1H, trip.), 3.31 (2H, sing.). 
Scheme 4.10. Selective sulfonyl cleavage of KAAI046 with base followed by 
acidic workup to yield KAAI048. 
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CONCLUSION 
The previous chapters have primarily been informative regarding a problem 
affecting antibiotic research and development. However, this chapter presents a 
perspective on the best course of action for the presented problem besides, or with further 
emphasis on, the avenues presented in Chapter 3. The antibiotic R&D issue discussed is 
not one with a clear antagonist. Although big pharma has decreased their investment in 
antibiotics, these companies are not necessarily to blame. They have simply pursued a 
business plan that will provide a sound financial return for the company and the investor. 
Currently, investment in blockbuster drugs is appealing financially. With this in mind, what 
is the most beneficial path to pursue in greater depth to address the matter in question?  
There are many different avenues that can be pursued (Chapter 3), but there are 
areas that should receive special attention. First, the increase in antibiotic resistance 
should persuade some big pharma companies to return to antibiotics as there is now a 
greater need for these drugs. Second, there needs to be increased publicity for bacterial 
infections such as TB. Third, the clinical trial process needs to be revised to alleviate 
extraneous costs. Fourth, the next generation of medicinal chemists needs to be inspired 
to simply do science. However, proposed solutions will never amount to much unless there 
is significant collaboration.  
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HOPE? RESISTANCE CREATES MARKET 
The increasing state of antibiotic resistance may actually encourage companies to 
return to antibiotic R&D. In the mid 1900’s infectious diseases were prevalent causing a 
strong interest from the pharmaceutical industry to develop antibiotics. Antibiotics were 
greatly needed as some of these diseases rose to epidemic levels. As a result there was 
a strong market demand for antibiotics.  
Currently, increased drug resistant infections, related morbidity, and a lean pipeline 
all push for the development of new antibiotic agents1. With increased antibiotic resistance 
there is an increase in the market for research and development of novel antibiotics. This 
is promising as R&D in this field is swinging back to the Gram-negative strains2 as Gram-
negative bacterial infections, such as TB, are exhibiting greater antibiotic resistance. 
Increased resistance has created a promising market opportunity for the pharmaceutical 
industry as the small market leads to high prices and the prospect of investment return for 
these companies2. Shales3 coined the phrase “markets create resistance and resistance 
creates markets”. The lack of funding for antibiotics has accelerated the problem of 
antibiotic resistance therefore increasing the market for research in this field, increasing 
the potential for the pendulum to swing back towards antibiotic R&D.  
Antibiotic resistance will encourage drug makers to invest in antibiotics. But, that 
is not the ideal incentive for companies to return to antibiotics. Big pharma is the discovery 
engine that can make real progress in the development of new antibiotics. They have the 
financial capital and resources to focus on antibiotic research and development. Should 
these companies allocate resources towards needed areas? Does big pharma need to 
see an epidemic to be willing to allocate resources towards antibiotics? An epidemic may 
encourage big pharma to refocus their attention towards antibiotics, however this perverse 
incentive should not be why new antibiotics are created. However, this may be the most 
effective incentive for big pharma. 
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HIV/AIDS PUBLICITY 
How can needed collaboration be achieved?  A small solution is increased publicity 
for bacterial diseases or specifically TB. It is unlikely to find an individual that does not 
think that the TB epidemic is a problem once the facts are presented before them. But, 
he/she may not originally understand the scale of the disease and the main problems 
involved in treating it because the disease is not publicized to a significant extent. 
Despite increasing efforts and progress in the 
fight against tuberculosis, the disease still remains 
one of the top worldwide killers4.  As previously 
mentioned TB is a disease associated with poverty. 
Comparably, human immunodeficiency virus/acquired 
immune deficiency syndrome (HIV/AIDS), was once 
considered a disease primarily associated with 
poverty, and it remains as one of the top ten global 
killers5. TB and HIV/AIDS are similar in global 
prevalence; however, TB is not as highly publicized in 
the United States as the HIV/AIDS epidemic. 
Because of the increased occurrence of 
HIV/AIDS in the United States among celebrities, the 
epidemic was thrust into the spotlight, causing it to 
receive significant support across the nation. Earvin 
“Magic” Johnson (Figure 5.1), the former Los Angeles 
Lakers basketball player, is arguably the most famous 
person diagnosed with HIV/AIDS. The disease 
caused him to retire from the Lakers, halting his 
career as an athlete6. Magic received a request to go 
public about his condition from AIDS activist Elizabeth 
Glaser, who contracted the disease from a blood 
transfusion while giving birth6. Since then, he has been a major advocate for the disease. 
He created the Magic Johnson Foundation, which gives teens college scholarships, hosts 
Figure 5.1. Earvin “Magic” 
Johnson. Former Los Angeles 
Laker, current HIV sufferer and 
major advocate. Founder of the 
Magic Johnson Foundation. 
Adapted from: 
http://www.howard.edu/newsroo
m/releases/2013/20130128Entre
preneurBasketballGreatMagicJoh
nsontoDiscussBusinessandHIVSt
igmaatHowardUniversityHospital.
html 
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job fairs, and health fairs. One of Magic’s main goals is to educate today’s young women 
so that they do not make the same mistakes he did.  
“We’re able to touch the community in so many different ways. And it’s very 
important to me that we do that and that people of color and the minorities that live 
in urban America know that they can come to Magic Johnson Foundation and 
Magic Johnson Enterprises for anything”6. 
Magic’s celebrity status helped in publicizing HIV/AIDS in the United States. 
Contrarily, the most famous cases of TB include the late Nelson Mandela, Tina Turner, 
and Ringo Starr7. Magic Johnson was a basketball player in the height of his career in the 
NBA. He had the money and the fame to become a large advocate for the disease. Nelson 
Mandela, arguably the most famous person affected with TB, was the president of South 
Africa.  He is an advocate for social justice and primarily works with third world issues. 
        Additionally, HIV/AIDS 
has received high publicity 
because of the nature of the 
disease. It should be noted 
that HIV is a viral disease, 
therefore it is not cured as 
easily as a bacterial 
infection. Magic Johnson 
still stresses that after 
twenty years of fighting it, 
he is still not cured of HIV. 
But, if a person contracts 
TB in the United States, 
they can be cured in 
approximately six months 
with the current drug regimen. Just four months after Mandela contracted TB he was 
cured8. Although this a long treatment for a bacterial disease, it is still significantly shorter 
than the twenty year fight Magic has been facing. Magic advocates for HIV/AIDS to 
prevent the future development of the disease in the United States. However, there is not 
Figure 5.2 South Africa’s former president contracted TB in 
1988 while imprisoned in Pollsmoor Prison in Cape Town. 
Adapted from: (7). 
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the same need for this type of advocacy for TB in the U.S. as the spread of disease can 
be avoided and it is still primarily a third world disease. But rather, the need for advocacy 
in the United States is to focus on treatments and ways to prevent patient compliance 
issues so that this can be addressed in developing countries where these issues are of 
greater concern. 
CLINICAL TRIALS 
Clinical trials are an obvious necessity for the development of a new antibiotic. The 
focus on ameliorating the antibiotic R&D funding burden should be on alleviating 
extraneous costs9 specifically in regards to the cost of clinical trials.  
From 1994 to 2003 funding for biomedical research more than doubled from $37.1 
billion to $94.3 billion10. In that time funding for clinical trials in the pharmaceutical industry 
increased from 37 to 64% of total biomedical research costs, but FDA approval of new 
molecular entities decreased by approximately 33% during that time10. This lack of 
productivity indicates that clinical trial practices are not as efficient as they need to be in 
drug development, therefore they need to be reassessed to decrease costs and increase 
efficiency. 
In a 2008 study, a panel of experts was hired to design clinical trial simulations to 
decrease costs. The team created two types of clinical trials; one that followed standard 
budgetary protocol and another that aimed to decrease costs by using a streamlined 
industry model. The main panel recommendations for the streamlined model includes “(1) 
increasing the ability of sites to be top performers; (2) using computer systems to improve 
site management and monitoring, and (3) streamlining and enhancing clinical trial 
operations”10. Recommendation 1 includes ideas such as using site facilities that best 
meet protocol requirements. Recommendation 2 includes ideas such as remote 
monitoring including conference calls and in house monitoring to decrease travel costs. 
Recommendation 3 includes ideas such as evaluation of cost-effectiveness of current 
practices with further research10. 
With the expert recommendations and a streamlined industry model, the cost of 
clinical trials was decreased by 68%. These recommendations could save the developing 
83 
 
companies hundreds of millions of dollars. Based on these results, revaluation of clinical 
trials to decrease costs is a promising avenue that should be pursued further. 
 
INSPIRING SCIENCE 
Chemists working at pharmaceutical companies are not intentionally ignoring 
antibiotics. They are working to do chemistry, because it is their passion. If the next 
generation of medicinal chemists can be inspired, then they will perform research to do 
science, and ideally not get caught up in the business plan. This is where academic 
research can play a role. Students that chose to pursue graduate studies are those that 
have decided they want to pursue research, at least for the time they are in graduate 
school. Antibiotic research should be pursued to a greater extent in the academic setting 
because of the students’ desire to learn. Because graduate school is primarily about 
learning and time is not as much of a factor, there is more freedom on which research 
path to pursue and a decreased pressure for production as compared to industry. If the 
students are inspired to do research at the graduate level, then they will hopefully take this 
inspiration with them as they enter the work force as medicinal chemists. 
 
THE CHALLENGE OF SCIENCE  
The majority of the previous writing has been devoted to addressing the issue of 
funding for antibiotic R&D. Even if these proposed solutions, and other previously existing 
ones, could solve the funding issue, there are still additional challenges to overcome. The 
main additional challenge is science. Even if scientists receive adequate funding, that 
does not necessarily mean that they will produce any significant results. This is because 
in reality science is hard. There are two main categories of rate limiting steps to the 
antibacterial discovery process. The first is identifying proper molecular targets, 
specifically ones that are not prone to resistance. The second is the limitation of chemical 
diversity, especially ones that are effective against Gram-negative organisms11. Within 
those categories include topics such as the types of antibiotic resistance, the challenge of 
discovering new classes of antibiotics, and many other complicated scientific issues.  
The point is that the lack of novel antibiotics is inherently more complex than just 
funding. There is no cure all for the issue. But, steps can be taken in more specific areas 
such as publicity, assessing clinical trials, and inspiring science. In all of these 
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collaboration needs to be an integral part. Only with collaboration can small steps be made 
in the perpetual fight against bacteria.   
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